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ABSTRACT 
 
VraSR two-component system rapidly senses the cell wall damage by antibiotics 
and positively modulates a set of genes (VraSR Regulon) to enhance the resistance 
phenotype in S. aureus. fmtA, murZ, sgtB and pbp2 are members of VraSR Regulon, and 
they are involved in cell wall peptidoglycan synthesis in response to cell wall inhibitors 
such as β-lactams. We investigated VraR binding activity on fmtA promoter/its mutants by 
in vitro and in vivo experiments. We found VraR can bind to two conserved motifs on 
fmtA promoter in the formation of a dimer and up-regulate the transcription of fmtA under 
oxacillin conditions. We also found fmtA had two transcription start sites: -157G was 
responsible for maintenance of a basal level expression, and -195G was induced by 
oxacillin treatment. We reported VraR/phosphorylated-VraR binding sequences on 
promoters of murZ, sgtB and pbp2. Putative transcription start sites of murZ, sgtB and 
pbp2 were also identified. 
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CHAPTER ONE: METHICILLIN-RESISTANT STAPHYLOCOCCUS 
AUREUS 
1.1 Pathogenesis and history of Staphylococcus aureus 
S. aureus is a Gram-positive bacterium belonging to the Micrococcaceae family. 
The organisms appear as grape-like clusters under the microscope (Lowy 1998). S. aureus 
causes multiple serious or fatal diseases such as bacteremia, endocarditis, metastatic 
infections, sepsis, toxic shock syndrome, pneumonia, and even food poisoning (Lowy 
1998). 
Human skin, especially the anterior area of the nares, is the main reservoir of S. 
aureus. Twenty percent of the human population are so-called persistent carriers, 
harboring one type of S. aureus strain. Approximately 60% of people, known as 
intermittent carriers, sporadically carry different strains (Kluytmans et al. 1997).  
S. aureus produces various types of virulence factors such as enzymes, toxins, or 
other cellular components that are involved in its ability to infect, colonize, or cause 
disease (Lowy 1998). S. aureus can secrete a wide range of enzymes depending on the 
strain. Hemolysins, nucleases, proteases, lipases, hyaluronidase, and collagenase may be 
involved in the digestion of host tissues and the spread of S. aureus. Some strains secrete 
exotoxins such as toxic-shock syndrome toxin-1, the staphylococcal enterotoxins, the 
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exfoliative toxins (including epidermolytic toxins A and B), and leukocidin that may 
impact the immune systems of hosts and have other biological functions (Dinges et al. 
2000; Lowy 1998). 
S. aureus was first discovered in the late 19th century and remains a common cause 
of infections from skin injuries or post-operative wounds in humans and other animals 
(Deurenberg and Stobberingh 2008). Before the use of penicillin for the treatment of S. 
aureus infections, the fatality rate reached 81.97% in 122 patients with S. aureus 
bacteremia (SAB) at Boston City Hospital (Skinner and Keefer 1941). Mortalities from 
SAB have declined significantly and continuously with the development of treatments, 
including antibiotics, in the last 70 years, but SAB is still fatal in 10-30% of patients (van 
Hal et al. 2012; Laupland 2013). 
1.2 Methicillin-resistant S. aureus (MRSA) 
The remarkable versatility of S. aureus under environmental pressure allows it to 
quickly acquire resistance to nearly all antibiotics used in treatments (Stryjewski 2014). 
The introduction of penicillin dramatically improved the prognosis of patients with S. 
aureus infections. Penicillin-resistant isolates of S. aureus, however, were identified in 
hospitals and later in communities only a few years after the medical introduction of 
penicillin (Rammelkamp and Maxon 1942). The resistance to penicillin was due to the 
production of an inducible β-lactamase (Rammelkamp and Maxon 1942; Bondi and Dietz 
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1945), and resistance spread quickly. By the late 1960s, more than 60% of the S. aureus 
strains in hospitals had acquired penicillin resistance, and 90% of S. aureus strains are 
now resistant through the production of β-lactamase (Finland 1955; Barber and 
Rozwadowska-Dowzenko 1948; Lowy 2003). 
Methicillin was developed in 1959 to combat the inactivation of penicillin by 
β-lactamase (Lowy 2003). Methicillin was derived from penicillin and was the first 
semisynthetic penicillinase-resistant penicillin (Figure 1.1). Methicillin was synthesized 
with the phenol group of benzylpenicillin disubstituted with methoxy groups, which 
significantly reduced its affinity to β-lactamase (Lowy 2003).  
Methicillin and other β-lactams achieved great early success in treating 
penicillin-resistant S. aureus. The first MRSA strain was reported just two years after its 
Figure 1.1 Chemical structure of Benzylpenicillin and Methicillin (Stapleton and 
Taylor 2002). 
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introduction but remained rare until the emergence of a multidrug-resistant MRSA in 
Europe in the 1960s (Jevons 1961; Otto 2012). Methicillin resistance is mainly due to the 
acquisition of the mecA gene from Staphylococcus sciuri7 (Stapleton and Taylor 2002). 
MRSA quickly disseminated worldwide from the 1970s with the emergence of novel 
lineages. The percentage of MRSA resistant to methicillin, oxacillin, and nafcillin 
increased from 2.4% to 29% from 1975 to 1991 in US hospitals (Panlilio et al. 1992). A 
survey by Diekema et al. (2001) indicated that roughly 20-70% of S. aureus isolates were 
resistant to β-lactams in most countries, regardless of geographic area.  
Extensive use of β-lactam antibiotics in the clinical treatment of S. aureus has been 
followed by the emergence and spread of MRSA. MRSA, originally named for the 
acquisition of methicillin resistance in S. aureus strains, have developed resistance to 
nearly all clinically used antibiotics, such as all β-lactams and vancomycin (Fan et al. 
2007; M 2013). 
The key mechanism of resistance to methicillin and other β-lactam antibiotics is 
based on the expression of the foreign gene mecA, which produces penicillin-binding 
protein 2a (PBP2a) (Stapleton and Taylor 2002). The targets of β-lactams are four natural 
penicillin-binding proteins (PBP1, PBP2, PBP3, and PBP4) that catalyze the cross-linking 
or transpeptidation reactions in the assembly of the peptidoglycan structure. The cell wall 
becomes vulnerable to internal osmotic pressure when the cross-linking of peptidoglycan 
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is inhibited by β-lactams, and the cells die. PBP2a has a lower penicillin-binding affinity 
relative to PBP2 (Pinho et al. 1998). PBP2a has similar penicillin-binding motifs as the 
other PBPs but much lower β-lactam binding activity, which compensates for the 
cross-linking of peptidoglycan under high doses of β-lactams (Stapleton and Taylor 
2002). 
During the 1990s, clones of community-acquired MRSA (CA-MRSA) from 
non-patient settings or from new patients with no history of MRSA infection were 
observed in Australia, Europe, North America, Latin America, and Asia. CA-MRSA, 
initially distinct from hospital-acquired MRSA (HA-MRSA) in phenotype, genotype, and 
antibiotic susceptibility, entered hospitals and merged with HA-MRSA (Deurenberg and 
Stobberingh 2008; Stryjewski and Corey 2014). 
Since the emergence of MRSA, the glycopeptide vancomycin became the treatment 
of choice against MRSA. Isolates of MRSA strains with intermediate vancomycin 
resistances were reported in Japan and then in other countries in 1997 (Lowy 2003). The 
first reported vancomycin-resistant S. aureus strain, Mu50, was heterogeneously resistant 
to vancomycin and so was still sensitive to vancomycin but produced some resistant 
subpopulations. These strains were found in approximately 20% of the hospitals in Japan 
(Hiramatsu et al. 1997).  
6 
 
Another serious concern is complete vancomycin resistance in some MRSA strains 
due mainly to an acquired foreign operon, vanA, which modifies the cell-wall precursor 
D-Ala-D-Lac, the target of vancomycin, to D-Ala-D-Ala, allowing the continued 
synthesis of peptidoglycan in the cell wall (CDC 2002; Lowy 2003). 
1.3 VraSR two-component system 
The mecA gene, encoding the 78-kDa PBP2a in MRSA isolates, plays an essential 
role in resistance to β-lactams. PBP2a, however, does not fully control the resistance 
phenotype of MRSA, and other factors such as the VraSR two-component system (TCS) 
coordinate the synthesis of cell-wall peptidoglycan and play an important role in 
expressing resistance to cell-wall inhibitors (de Lencastre et al. 1994). 
1.3.1 Two-component systems 
TCSs are signal-transduction systems in bacteria and usually play important roles in 
the expression of virulence factors and in adaptations to environmental pressures and 
changes (Kawada-Matsuo et al. 2011). 
The predominant mechanism of such signal-transduction systems is a pathway of 
phosphotransfer, and its core components are two conserved proteins, a sensor histidine 
protein kinase (HK) and a cognate response regulator (RR). HK, which is regulated by 
environmental stimuli, catalyzes autophosphorylation at a conserved histidine (His) 
residue, creating a high-energy phosphoryl group that is subsequently transferred to an 
7 
 
aspartic acid residue in the response-regulator protein. The phosphotransfer is catalyzed 
by the conserved regulatory domain of RR. Phosphorylation of RR induces a 
conformational change in the regulatory domain that activates RR, which subsequently 
triggers intracellular responses, most often the regulation of gene expression and 
enzymatic activity in some cases (Stock et al. 2000).  
1.3.2 VraSR Two-component System 
Exposure of S. aureus to inhibitors of cell-wall synthesis, e.g. β-lactams and 
vancomycin, is followed by dramatic changes in the transcription of a number of genes. 
The VraSR two-component system is capable of rapidly sensing damage to cell walls and 
regulating a unique set of genes known as the VraSR regulon (Gardete et al. 2006; 
Belcheva and Golemi-Kotra 2008). 
Utaida et al. (2003) reported the existence of a cell-wall-stress stimulon that 
included 105 genes up-regulated by the cell-wall-active antibiotics oxacillin, bacitracin, 
and D-cycloserine, which inhibit different steps in peptidoglycan biosynthesis. The VraSR 
regulon is part of this stimulon. Similarly, Kuroda et al. (2003) identified a 
vancomycin-induced cell-wall-stress stimulon that included 139 genes in S. aureus N315, 
and 46 of these genes under the regulation of the VraSR two-component system were 
considered to belong to the VraSR regulon. Gardete et al. (2006) confirmed the existence 
of the VraSR regulon in MRSA and laboratory strains. The VraSR two-component system 
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is able to sense and regulate the expression of PBP2 in S. aureus and to coordinate a rapid 
response to enhance the resistance to peptidoglycan inhibitors (Gardete et al. 2006). 
Sengupta et al. (2012) provided direct in vivo evidence of the VraSR regulatory 
mechanism previously proposed by Belcheva and Golemi-Kotra (2008). According to this 
mechanism (Figure 1.2), VraS is a typical HK with an N-terminal transmembrane domain 
and a conserved C-terminal HK core. The N-terminal transmembrane domain of VraS 
consists of two membrane-spanning regions that are connected by a periplasmic linker. 
The conserved HK core of VraS contains the dimerization domain, which has the 
conserved His residue, and the ATP-binding domain. VraR is a two-domain 
response-regulator protein containing a conserved N-terminal regulatory domain and a 
C-terminal DNA-binding domain, referred to as the effector domain. Environmental 
stimuli are transduced through the membrane to the conserved HK core domain and 
trigger the autophosphorylation of HK at the conserved His residue. The phosphoryl 
groups are rapidly transferred to the cognate RR in an RR-catalyzed reaction. 
Phosphorylation of VraR induces a specific conformational change and forms a dimer at 
the N-terminal domain. Phosphorylated VraR binds to the promoter regions of its target 
genes and increases the transcription levels to compensate for the damage to the structure 
of cell-wall peptidoglycan.  
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1.4 Research Objectives 
Inhibitors of cell-wall synthesis, such as β-lactams and vancomycin, are still widely 
used in current therapies for S. aureus infections. A better understanding of the 
mechanism of MRSA resistance to these compounds may allow us to find new drug 
targets or to develop new antibiotics. This study focuses on the genes associated with the 
biosynthesis of cell-wall peptidoglycan that are under the control of the VraSR 
two-component system. These genes are potentially important drug targets. The VraR 
binding activities at the promoters of fmtA, murZ, sgtB, and pbp2 and the regulatory 
mechanism are investigated.  
  
Figure 1.2 The schematic representation of VraSR two-component system(shown 
are the amino acid positions where the predicted domains start and end in VraS and 
VraR; H, the histidine box; ATP, the ATP-binding domain; R, the receiver domain; 
and ED, the DNA-binding domain; domain prediction by ExPaSY) (Belcheva and 
Golemi-Kotra 2008). 
10 
 
CHAPTER TWO: DETERMINATION OF VRAR BINDING 
ACTIVITY AT THE PROMOTER OF FMTA IN VITRO 
2.1 Introduction 
2.1.1 Regulation of fmtA transcription under antibiotic-induced cell-wall stress 
 The fmtA gene encodes FmtA, a low-affinity penicillin-binding protein, and is a 
member of the VraSR regulon family involved in peptidoglycan biosynthesis under 
antibiotic (cell-wall inhibitors) conditions in S. aureus (Fan et al. 2007; Utaida et al. 2003; 
Kuroda et al. 2003; McAleese 2006; Muthaiyan et al. 2008). The precise function of FmtA is 
still unclear, but some characteristics of the fmtA gene and its regulatory mechanism have 
been clarified (Komatsuzawa 1999; McAleese et al. 2006; Zhao et al. 2012; Fan et al. 
2007; Tu et al. 2007; Sengupta et al. 2012). 
The level of transcription of fmtA increases in the presence of cell-wall inhibitors 
(e.g. vancomycin and β-lactams) (McAleese et al. 2006; Zhao et al. 2012; Komatsuzawa 
1999). Inactivation of fmtA reduces the level of cross-linking in peptidoglycan and the 
rate of autolysis of S. aureus in the presence of Triton X-100 (a detergent capable of 
solubilizing membrane-associated proteins) (Komatsuzawa 1999). The fmtA mutant of S. 
aureus produces no teichoic acid and reduces biofilm formation by a structural change in 
the cell wall (Zhao et al. 2012; Tu et al. 2007).  
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2.1.2 Current understanding of VraR binding activity at the fmtA promoter 
The fmtA gene is 1191 base pairs (bp) long, and its promoter region (PfmtA) is 450 
bp immediately upstream of the translation initiation codon (ATG). All DNA fragments 
and sequences of fmtA or PfmtA used in this study are based on the S. aureus subsp. Mu50 
strain, an MRSA strain with vancomycin resistance whose genome has been sequenced 
(Kuroda et al. 2001). The top strand in this study is the sense strand, and the bottom 
strand is the antisense strand. Position +1 refers to the A of the start codon ATG in the top 
strand, and so on. 
The fmtA promoter has two VraR-specific binding sites, here named A1 and A2 
(Figure 2.1a and 2.1b). Based on the DNase I footprinting assays, the A1 site is protected 
only by phosphorylated VraR, and the A2 site is protected by both phosphorylated and 
unphosphorylated VraR. The protection occurs on both the top and bottom strands.  
Belcheva et al. (2009) found two VraR binding motifs in the vraSR promoter: 
5’-ACT(X)nAGT-3’ and 5’-TGA(X)nTCA-3’, where X is any nucleotide and n = 1-3. A 
specific region, -241ACTttAGTaTGAtgTCt-225, in the A2 site is highly conserved with the 
VraR binding site R1 (ACTaaAGTaTGAacaTCa) in the vraSR promoter (Belcheva et al. 
2009), and both of the two conserved regions include the two identified VraR binding 
motifs (Figure 2.1b). But A1 does not have similar motifs (Figure 2.1b). 
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Mutations at the cytosine (C) and guanine (G) nucleotides in the conserved region 
caused obvious decreases in the affinity of VraR binding at PfmtA. The Cs and Gs 
(underlined) in the conserved subregions 5’-ACTttAGT-3’ and 5’-TGAtgTCt-3’ in the full 
fmtA promoter were mutated, and the mutated subregions were then inserted into lux 
fusion plasmids, where the addition of a functional promoter region increased the 
expression of bioluminescent signals in S. aureus. Both double mutations caused a loss of 
up-regulation of the bioluminescent signals relative to the wild-type promoter, suggesting 
that VraR might bind to these two motifs in pairs (phosphorylated VraR is a dimer). I 
proposed that this dimer could be separated to eliminate the binding of VraR if additional 
nucleotides were inserted into the interior of these two motifs. I also hypothesized that the 
mutagenesis of C and G in the VraR binding motifs may help to reveal the VraR binding 
activity and motifs at A1 as it did in the vraSR promoter (Belcheva et al. 2009). 
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Figure 2.1 fmtA promoter region in the S. aureus strain Mu50. a) 450bp region 
between fmtA and SAV1056 genes is considered as promoter of fmtA (PfmtA). VraR 
binding sites A1 and A2 identified in this study are shown. b) DNA sequence of 
PfmtA. A1 and A2 sites are indicated with red and purple dash lines. Conserved VraR 
binding sequences (double-underlined) including two VraR binding motifs (two 
boxes) are shown. Two transcription start sites identified in this study are indicated 
with “*”, and corresponding -10 regions are underlined with round dots. 
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2.2 Materials and Methods 
2.2.1 Generation of mutants of the fmtA promoter 
The full fmtA promoter (PfmtA, nucleotides -498 to +42) was inserted into the 
pSTBlue-1 blunt-ended vector (Novagen) by V. Verma in Dr. Golemi-Kotra lab. EcoRI 
(gccGAATTC) and BamHI (GGATCCggc) sites were added to the 5’ and 3’ ends of this 
region, respectively (unpublished). (Lower letters represent additional nucleotides added 
for the convenience of restriction enzyme digestion.) Six single/double mutants were 
generated from the above plasmid (Figure 2.2; Table 2.1). Mutant 1 (M1) possessed an 
additional adenine (A) at position -233 of A2 (-233A/AA). Mutant 2 (M2) had the C at 
-356 replaced by an A. Mutant 3 (M3) had the C at -356 and the G at -349 replaced by A 
and thymine (T), respectively. Mutant 4 (M4) had the Cs at -373 and -367 replaced by As. 
Mutant 5 (M5) had the Cs at -363 and -356 replaced by As. Mutant 6 (M6) had the G at 
-339 and the C at -333 replaced by T and A, respectively.  
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Table 2.1 Primers designed for the generation of six mutants of the fmtA promoter by 
QuikchangeTM Site-direct Mutagenesis Kit (Stratagene). Red-highlighted letters 
indicate the mutated nucleotides.  
Primer name Primer sequence Mutations 
A2A22AA FWD 5’ – 
GCGACTTTAGTAATGATGTCTTAAAAAA
TTTAAAGGC 
M1, 
-233A/AA  
A2A22AA REV 5’ – 
GCCTTTAAATTTTTTAAGACATCATTACT
AAAGTCGC 
A1C22A FWD 5’ – 
CTTCATTACTAATAAATTATAGCCTTAAA
TTGTAGTACTTTATAG 
M2, 
-356C/A 
A1C22A REV 5’ – 
CTATAAAGTACTACAATTTAAGGCTATA
ATTTATTAGTAATGAAG 
A1C22A/G29T 
FWD 
5’ – 
CTTCATTACTAATAAATTATATCCTTAAA
TTGTAGTACTTTATAG 
M3, 
-356C/A& 
-349G/T 
A1C22A/G29T 
REV 
5’ – 
CTATAAAGTACTACAATTTAAGGATATA
Figure 2.2 Sequences of VraR binding-sites A1 and A2 in PfmtA and there mutants. 
Five mutants were derived from the A1 site: M2, M3, M4, M5 and M6. One mutant 
was derived from the A2 site: M1. Underlined sequences indicate the targeted 
mutation sites and the red-highted sequences indicate mutated nucleotides in each 
mutant. 
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ATTTATTAGTAATGAAG 
A1C5A/C11A  
FWD 
5’ – 
GTTGAACGATATTTATAAAACTTAATTA
CTAATACATTATAGCC 
M4, 
-373C/A& 
-367C/A 
A1C5A/C11A  
REV 
5’ – 
GGCTATAATGTATTAGTAATTAAGTTTTA
TAAATATCGTTCAAC 
A1C16A/C22A 
FWD 
5’ – 
GATATTTATACAACTTCATTAATAATAAA
TTATAGCCTTAAATTG 
M5, 
-363C/A& 
-356C/A 
A1C16A/C22A 
REV 
5’ – 
CAATTTAAGGCTATAATTTATTATTAATG
AAGTTGTATAAATATC 
A1G39T/C45A 
FWD 
5’ – 
GCCTTAAATTTTAGTAATTTATAGTAAA
AAATACAAATGTTATG 
M6, 
-339G/T& 
-333C/A 
A1G39T/C45A 
REV 
5’ – 
CATAACATTTGTATTTTTTACTATAAATT
ACTAAAATTTAAGGC 
The QuikChangeTM Site-Directed Mutagenesis Kit (Stratagene) was used for the 
mutagenesis. Primers designed for generation of mutagenisis were shown in Table 2.1. 
The following PCR conditions were used: 95 °C for 2 min, 16 cycles of 95 °C for 45 s, 
55 °C for 1 min, 68 °C for 6.5 min, and a final extension step of 68 °C for 5 min. 
PCR-amplified plasmids were digested by DpnI and then transformed by heat shock into 
NovaBlue competent E. coli cells that were grown on LB plates containing 50 µg/mL 
kanamycin. Colonies were picked, and the plasmids were extracted using Qiagen plasmid 
mini kit and then examined by DNA sequencing. 
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2.2.2 Purification and Phosphorylation of VraR 
The vraR gene had previously been inserted into the pET26b vector, which had then 
been transformed into E. coli BL21 (DE3) expression cells (Belcheva et al. 2009). The 
cells were grown in TB (define acronym) medium, and protein expression was induced by 
0.4 mM IPTG (define acronym) at 25 °C for 16 h. The cell pellet was dissolved in 
equilibration buffer (20 mM Tris and 5 mM MgCl2, pH 7.0). After sonication, the 
supernatant was loaded onto a DEAE Sepharose column and then eluted by elution buffer 
(500 mM Tris and 5 mM MgCl2, pH 7.0). Fractions containing VraR were loaded onto 
heparin-Sepharose columns and then eluted by the same elution buffer as above. The 
collected fractions containing VraR were concentrated by Ultra 10K filters (Amicon; 
10,000 NMWL). The final concentration of VraR was determined by a Bradford assay 
after electrophoresis on a 15% SDS-PAGE gel. 
VraR was phosphorylated as described previously (Belcheva et al. 2009), with 
slight modifications. MgCl2 and lithium potassium acetyl phosphate dissolved in 
phosphorylation buffer (50 mM Tris-base, pH 7.4, 50 mM KCl, and 5 mM MgCl2) were 
mixed with 150 μM VraR to obtain a solution containing 100 μM VraR, 20 mM MgCl2, 
and 50 mM lithium potassium acetyl phosphate. The reaction was incubated at 37 °C for 
1 h, and phosphorylation activity was confirmed by electrophoresis on a 10% native 
polyacrylamide gel. The content of phosphorylated VraR (VraR-P) under our 
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experimental conditions was approximately 70% (Belcheva and Golemi-Kotra 2008). 
VraR~P thus refers to a mixture of phosphorylated and unphosphorylated VraR. 
2.2.3 DNase I footprinting assays to investigate the VraR binding activity at the fmtA promoter 
and its mutants 
The target DNA fragment, -394 to -199 of the fmtA promoter region, referred to as 
seq1-3 which contains both A1 and A2 sites, was PCR-amplified using the forward primer 
5'-ATTAGTTGAACGATATTTATAC and the reverse primer 
5'-GAATTTATATTACGCCTTTAAAT. The following PCR conditions were used: 95 °C 
for 2 min, 30 cycles of 95 °C for 20 s, 55 °C for 30 s, 72 °C for 30 s, and a final extension 
step of 72 °C for 5 min. A target fragment A1S (from -425T to -299T, containing only A1) 
was PCR-amplified using the forward primer 5’- TGTTAAATCATAATCATAAT and the 
reverse primer 5’- ACTTTGACATAACATTTG. The same PCR conditions were used as 
the PCR-amplification of seq1-3. 
All amplified DNA fragments were purified using the QIAquick Gel Extraction Kit 
(Qiagen) and used as PCR templates in DNase I footprinting assays. The 5’end of the 
primer of interest (the forward primer for the investigation of the top strand or the reverse 
primer for the investigation of the bottom strand) was labeled with [γ-32P] ATP (3000 
Ci/mmol) using 20 U of T4 polynucleotide kinase (NEB) and was used to amplify seq1-3 
in a 20-µL reaction. Binding reactions were prepared in binding buffer (10 mM Tris, pH 
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7.5, 50 mM KCl, and 1 mM DTT) supplemented with 5 mM MgCl2, 0.05% herring sperm 
DNA, and 2.5% glycerol. The end-labeled DNA (6-15 ng) was mixed with VraR/VraR~P 
at concentrations ranging from 0 to 40 μM. Binding reactions were incubated for 30 min 
at room temperature and then digested with DNase I (0.024 U/reaction) for 2 min. The 
digestions were stopped by adding 50 μL of DNase I stop solution (1% SDS, 0.2 M NaCl, 
and 20 mM EDTA, pH 8.0). Digested DNA samples were extracted by phenol-chloroform 
and then precipitated with ethanol. Purified DNA was resuspended in loading dye 
containing 10 mM formamide, 1 mg/mL bromophenol blue, and 1 mg/mL xylene cyanol, 
heated at 95 °C, and electrophoresed on an 8% polyacrylamide gel containing 7 M urea. 
The dried gels were exposed to phosphor screens and scanned using a Typhoon Trio+ 
variable-mode imager (GE HealthCare). The C and G sequencing reactions for these 
experiments were performed in 10-µL PCR reactions containing 1 µL of end-labeled 
primer, 0.5 µL of Therminator DNA polymerase, 50 nM dNTPs, 1.9 µM acyGTP or 
acyCTP, and 25 ng of template DNA (gel-purified seq1-3). 
2.2.4 Electrophoretic mobility shift assay (EMSA) 
The target DNA fragments were generated with synthesized primers (Sigma) (Table 
2.2). A1a, A1b and A1c, derived from the A1 site, were defined in Table 2.2.  
Table 2.2 Primers (5’ to 3’) used to generate double-stranded DNA fragments for the 
EMSAs. The red-highlighted letters represent the mutated nucleotides. 
Primer Primer sequences Position of annealed 
dsDNA fragment in PfmtA 
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fmtAPtopA1 GATATTTATACAACTTCATTA
CTAATACATTATAGCCTTAA
ATTGTAGTACTTTATAGTAA 
Region -383 to -323, 
containing the full VraR 
binding-site A1 in PfmtA 
fmtAPbotA1 TTACTATAAAGTACTACAAT
TTAAGGCTATAATGTATTAG
TAATGAAGTTGTATAAATAT
C 
fmtAPtopA2 TTAAAAATATAATGCGACTT
TAGTATGATGTCTTAAAAAA
TTTAAAGGC 
Region -257 to -209, 
containing the full VraR 
binding-site A2 in PfmtA 
fmtAPbotA2 GCCTTTAAATTTTTTAAGAC
ATCATACTAAAGTCGCATTA
TATTTTTAA 
fmtAPtopM1 TTAAAAATATAATGCGACTT
TAGTAATGATGTCTTAAAAA
ATTTAAAGGC 
Full VraR binding-site A2 in 
PfmtA, containing M1, 
-233A/AA  
fmtAPbotM1 GCCTTTAAATTTTTTAAGAC
ATCATTACTAAAGTCGCATT
ATATTTTTAA 
fmtAPtopM4 GATATTTATAAAACTTAATTA
CTAATACATTATAGCCTTAA
ATTGTAGTACTTTATAGTAA 
Full VraR binding-site A1 in 
PfmtA, containing M4, 
-373C/A & -367C/A 
fmtAPbotM4 TTACTATAAAGTACTACAAT
TTAAGGCTATAATGTATTAG
TAATTAAGTTTTATAAATATC 
fmtAPtopM6 GATATTTATACAACTTCATTA
CTAATACATTATAGCCTTAA
ATTTTAGTAATTTATAGTAA 
Full VraR binding-site A1 in 
PfmtA, containing M6, 
-340G/T & -333C/A 
fmtAPbotM6 TTACTATAAATTACTAAAAT
TTAAGGCTATAATGTATTAG
TAATGAAGTTGTATAAATAT
C 
fmtAP A1aTop GATATTTATACAACTTCATTA
CTAATAC 
A1a, part of the VraR 
binding-site A1 in PfmtA, 
-383 to -356 fmtAP A1aBot GTATTAGTAATGAAGTTGTA
TAAATATC 
fmtAP A1aTopM4 GATATTTATAAAACTTAATTA
CTAATAC 
Ala containing M4 
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fmtAP A1aBotM4 GTATTAGTAATTAAGTTTTAT
AAATATC 
fmtAP A1bTop ATTATAGCCTTAAATTGTAG
TACTTTATAGTAA 
A1b, part of the VraR 
binding-site A1 in PfmtA, 
-355 to -323 fmtAP A1bBot TTACTATAAAGTACTACAAT
TTAAGGCTATAAT 
fmtAP A1bTopM6 ATTATAGCCTTAAATTTTAGT
AATTTATAGTAA 
A1b containing M6 
fmtAP A1bBotM6 TTACTATAAATTACTAAAAT
TTAAGGCTATAAT 
fmtAP A1cTop TGAACGATTAATACATTATA
AAAAATA 
A1c, containing part of the 
VraR binding-site A1 in 
PfmtA, including regions 
-388 to -381, -361 to -352, 
& -325 to -317 
fmtAP A1cBot TATTTTTTATAATGTATTAAT
CGTTCA 
VraR/VraR~P binding affinities with seq1-3 were also investigated by EMSAs. The 
seq1-3 was obtained by PCR using the primers: 5'-ATTAGTTGAACGATATTTATAC-3’ 
and 5'-GAATTTATATTACGCCTTTAAAT-3’. The following PCR conditions were used: 
95 °C for 2 min, 30 cycles of 95 °C for 20 s, 55 °C for 30 s, 72 °C for 30 s, and a final 
extension step of 72 °C for 5 min. The amplified DNA fragments were purified by 
QIAquick Gel Extraction Kit (Qiagen). 
The DNA fragments (1.245 pmol) were labeled with [γ-32P]ATP (3000 Ci/mmol) 
using T4 polynucleotide kinase. Binding reactions (20 μL) were prepared in binding 
buffer (10 mM Tris, pH 7.5, 50 mM KCl, and 1 mM DTT) supplemented with 5 mM 
MgCl2, 10 ng of herring sperm DNA, and 2.5% glycerol. Target DNA (0.03 pmol) was 
mixed with protein concentrations varying from 0 to 35 μM. The reaction mixtures were 
incubated at 25 °C for 30 min and electrophoresed on 8%-10% native polyacrylamide 
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gels (seq1-3 on 8% gels and primer-annealed DNA fragments on 10% gels). Dried gels 
were exposed to phosphor screens (GE HealthCare), with the time of exposure depending 
on the remaining level of radioactivity. The gel was then scanned by a Typhoon Trio+ 
variable-mode imager (GE HealthCare) and analyzed by ImageJ software. Kd was defined 
as the concentration of VraR/VraR~P (µM) required to shift 50% of the input DNA. 
2.3 Results 
Gs and Cs normally play an important role in typical VraR binding motifs, and 
mutations of G or C nucleotides significantly decrease the affinity of VraR binding to the 
corresponding motifs (Belcheva et al. 2009). By closely examining the features of the 
VraR binding-site A1 of the fmtA promoter, I predicted which Gs or Cs were essential for 
the binding of VraR. Variants containing mutations of these Gs and Cs were generated, 
and the effects of these mutations on VraR binding activity were investigated by in vitro 
and in vivo experiments (Figure 2.2). A highly conserved VraR binding region was 
identified on the VraR binding-site A2. An A had been inserted into this motif, and I 
hypothesized that this additional nucleotide would interrupt the formation of 
phosphorylated VraR dimers. 
2.3.1 Generation of fusion plasmids containing PfmtA mutants 
A fusion plasmid had previously been prepared by inserting the fmtA promoter 
region -498 to +42 into the pSTBlue-1 vector by Belcheva in Dr. Golemi-Kotra lab. Five 
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single- or double-nucleotide mutants (M2-M6) targeted to VraR binding-site A1 were 
derived from this plasmid to investigate the role of the Gs and Cs. One single-nucleotide 
mutant (M1) targeted to VraR binding-site A2 was also derived. All mutations were 
confirmed by sequencing (Figure 2.2).  
2.3.2 Purification of VraR 
Wild-type VraR was purified in a two-step protocol. Peak fractions containing VraR 
were collected at elution-buffer contents of 20-30% on a DEAE sepharose column and 
were then loaded onto a heparin-Sepharose column (Figure 2.3a). In the second step, 
purified VraR was observed in the peak fractions at elution-buffer contents of 40-60% 
(Figure 2.3b). Purified VraR was stored at 4 °C, which maintained stability for 2-4 weeks. 
 
Figure2.3 Typical procedure of purification of VraR by FPLC. (a) first-step 
purification by DEAE sepharose column. The peak containing VraR is typically 
observed around 20% to 30% of elution buffer. (b) second-step purification by 
Heparin sepharose column. The peak (λ280nm) contains pure VraR was typically 
observed around 40% to 60% of elution buffer. Y axis: Content of elution buffer (%); 
X axis: Order numbers of collection tubes; The blue and yellow lines represent protein 
absorbance at λ280nm and content of elution buffer (%). 
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2.3.3 DNase I footprinting assays  
The VraR binding-site A1 had previously been determined to be protected only by 
VraR~P, and A2 was protected by both VraR and VraR~P (A. Belcheva in Dr. 
Golemi-Kotra lab, unpublished).  
VraR binding-site A1 in PfmtA was protected only by VraR~P in the DNase I 
footprinting assays, and the site had little sequence similarity with the previously 
identified VraR binding motifs in the vraSR promoter (Belcheva et al. 2009). Since G and 
C usually play an important role in VraR binding (Belcheva et al. 2009), I generated five 
mutants to investigate whether VraR~P binding activity was affected by mutation of the 
putatively essential nucleotides (Figure 2.2). Replacement of -373C and -367C (M4) 
reduced VraR~P binding activity at A1 from -380 to -363 of the top strand and from -378 
to -366 of the bottom strand (Figure 2.4 and 2.6). Replacement of -339G and -333C (M6) 
had a similar effect on VraR~P binding activity at A1 from -339G to -326G of the top 
strand and from -345T to -329A of the bottom strand (Figure 2.5 and 2.6). Both M4 and 
M6 decreased VraR~P binding activity at sequences near -356C. The effect of M4 and 
M6 at A1 was much weaker than the effect of M1 on VraR binding at A2 (Figure 2.7). 
The other mutants (M2, M3, and M5) had no significant effect on VraR/VraR~P binding 
compared to the wild type (data not shown). 
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I found a VraR binding region in A2 that was similar to the VraR binding site R1 in 
the vraSR promoter: -241ACTttAGTaTGAtgTCt-225. VraR bound as a dimer at this site 
(Figure 2.1b). The double mutations -240C/-235G or -231G/-226C prevented increases in 
fmtA expression under oxacillin treatment (add initial of first name Verma in Dr. 
Golemi-Kotra lab, unpublished). I investigated the effect of M1 on VraR binding activity 
and on the ability of VraR to bind as a dimer. The insertion of an A after -233 separated 
these two VraR binding motifs. An investigation of the bottom strand of seq1-3 indicated 
that VraR and VraR~P protected the same region from -251 to -225 from DNase I 
digestion. Interestingly, M1 caused an almost complete loss of both VraR and VraR~P 
binding activity at the A2 site, but the A1 site was not affected by M1 (Figure 2.7).  
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a  b
Figure 2.4 DNase I footprinting assays showed VraR~P binding activity on the top 
strands of DNA fragments containing A1 site or its mutant M4.   
(a)VraR~P binding activity on the top strand of A1S (from -425T to -299T, contains 
A1 site only) and its mutant M4. (b) VraR~P binding activity on the top strand of 
seq1-3 (-394 to -199, containing both A1 and A2) and its mutant M4. (only 
M4-affected region was shown). Blue solid lines indicate same region containing 
M4-affected region on both target DNA fragments. The dashed line indicates 
M4-affected region (from –380A to –356C). –356C is a single nucleotide affected by 
M4. –373C/A and –367C/A indicate two mutated nucleotides of M4. Lane G and C 
represent the G/C ladders, respectively. 
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Figure 2.5 DNase I footprinting assays showed VraR~P binding activity on the top 
strands of DNA fragments containing A1 site or its mutant M6.   
(a)VraR~P binding activity on the top strand of A1S (from -425T to -299T, contains 
A1 site only) and its mutant M6. (b) VraR~P binding activity on the top strand of 
seq1-3 (-394 to -199, containing both A1 and A2) and its mutant M6. (only 
M6-affected region was shown). Blue solid lines indicate same region containing 
M6-affected region on both target DNA fragments. The dashed line indicates 
M6-affected region (from –339G to –326G). –356C is a single nucleotide affected by 
M6. –333C/A and –339G/T indicate two mutated nucleotides of M6. Lane G and C 
represent the G/C ladders, respectively. 
a  b
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Figure 2.6 DNase I footprinting assays showed VraR~P binding activity on bottom 
strands of A1S (from -425T to -299T) containing A1 site or its mutant M4/M6. 
The dash-dot line indicates the M6-affected region (from –345T to –329A), and the 
dashed line indicates the M4-affected region (from –378T to –366A). –356C 
represents a single nucleotide affected by both M4 and M6. –373C/A and –367C/A 
indicate two mutated nucleotides of M4. –339G/T and –333C/A indicate two mutated 
nucleotides of M6. Lane G and C represent the G and C ladders, respectively. 
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Figure 2.7 DNase I footprinting assays showed VraR~P and VraR binding activity on 
bottom strands of seq1-3 containing A2 site or its mutant M1. 
(a) VraR~P binding activity on the bottom strands of seq1-3 and its mutant M1. (b) 
VraR binding activity on the bottom strands of seq1-3 and its mutant M1. Dashed lines 
indicate M1-affected regions (the same region, from –251A to –225T, affected by M1 
on both gels). Double-arrowheads indicate the mutated nucleotide on M1 where one 
Adenine is replaced by two Adenines. Lane G and C represent G and C ladders, 
respectively. 
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2.3.4 Electrophoretic mobility shift assay (EMSA)  
EMSA assays investigated the effect of three PfmtA mutants, M1, M4, and M6, on 
the binding affinity of VraR/VraR~P at PfmtA (Figure 2.8 and Appendix Figure3). These 
mutants decreased VraR/VraR~P binding in the DNase I footprinting assays.  
The insertion of an Adenine in A2 (mutant A2-M1) significantly decreased the 
binding affinities of VraR (Kd value increased from 5.9±0.12 to 12.3±2.52 µM) and 
VraR~P (Kd value increased from 5.6±0.12 to 9±0.89 µM) at the A2 site (Figure 2.8). 
A1-M4 and A1-M6 caused no obvious change in VraR~P binding affinity relative to the 
affinity at the wild-type A1 site. 
The Kd values of VraR/VraR~P binding at the seq1-3 were 7.2±0.5 µM and 
5.5±1.02 µM, respectively, which were close to the Kd values of VraR/VraR~P binding at 
the A2 site, while significantly lower than that of the A1 site (Figure 2.8).  According to 
the data of DNase I footprinting assays, A1a region is affected by M4, A1b is affected by 
M6, and A1c is affected by both M4 and M6 when DNase I digestion occurs. Three short 
DNA fragments were derived from A1 based on the regions affected by M4/M6 in the 
DNase I footprinting assays (Figure 2.9). A1a contained the region affected by M4, A1b 
contained the region affected by M6, and A1c contained the interior region of A1 that was 
affected by both M4 and M6. To look closely at the VraR binding activity in the A1 site, 
EMSA assays were also conducted to investigate VraR/VraR~P binding affinities at A1a, 
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A1b, and A1c (Figure 2.9). A1a containing M4 and A1b containing M6 were also 
generated by primer annealing and were used in the EMSA assays (Table 2.2). All DNA 
fragments had very low VraR~P binding affinity, and Kd values could not be determined, 
because they were beyond the range of the protein concentrations on the EMSA gels 
(Figure 2.10 and Appendix Figure 1). No VraR binding activity was observed for any of 
the fragments. Binding activity did not differ between the wild-type fragments and their 
mutants.  
 
Figure 2.8 EMSA analysis of the DNA-binding affinities of VraR/VraR~P to 
seq1-3, A1, A2 and their variants (representative gels shown in Appendix Figure 
3). Red columns indicate VraR/VraR~P binding to seq1-3. Green columns 
indicate VraR binding to A2 and its mutant M1. Yellow columns indicate VraR~P 
binding to A2 and its mutant M1. Blue columns indicate VraR~P binding to A1 
and its mutants M4 and M6. Means of Kd values and standard deviations were 
calculated from at least three independent experiments. Kd was defined as the 
concentration of VraR/VraR~P (µM) required to shift 50% of the input DNA. 
32 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10 Investigation of VraR/VraR~P binding affinity on A1a by EMSA. 
A1a-M4, A1b, A1b-M6 and A1c showed similar gel patterns. Rest images shown 
in Appendix Figure 1. Kd values could not be determined accurately due to the 
range of available protein concentrations prepared in EMSA procedure.  
A1 site 
Figure 2.9 M4-affected and M6-affected regions within the VraR binding site 
A1 are shown. A1a, A1b and A1c contain nucleotides on upstream and/or 
downstream of A1 site to obtain longer DNA fragments for EMSA assays. 
Green-highlighted nucleotides indicate where the mutation occurs on M4. 
Blue-highlighted nucleotides indicate where the mutation occurs on M6. All 
the fragments used in EMSA were obtained by primer annealing method. 
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2.4 Discussion 
The A2 site in PfmtA had two VraR binding motifs, which were highly conserved 
with previously identified binding motifs in the VraR binding site R1 of the vraSR 
promoter (Belcheva et al. 2008). The entire A2 site lost the protection by VraR or VraR~P 
under DNase I digestion when an A was inserted between these two motifs, suggesting 
that the inserted nucleotide may have separated the dimerized VraR or changed its 
structural conformation so that it lost the ability to bind to A2. I  propose that two VraR 
monomers are able to bind to two binding motifs independently, in agreement with the 
protection of A2 from DNase I digestion by unphosphorylated VraR. The loss of 
protection from DNase I digestion by both VraR and VraR~P caused by the inserted 
nucleotide between the two motifs, however, suggests that only the VraR dimer can bind 
to A2, and when the dimerization is disrupted by the inserted nucleotide, the ability of the 
VraR monomers to bind to specific motifs is lost or dramatically decreased. When 
unphosphorylated, the two VraR monomers may not be able to bind to A2 unless they are 
able to form a dimer.  
A1 had fewer conserved features in its sequence and was only protected by 
phosphorylated VraR. The effects of mutants M2-M6 on VraR binding to A1 were much 
weaker than the effect of M1 on VraR~P binding to A2, suggesting that A2 may be the 
major functional site responsible for the regulation of fmtA transcription by VraR. I 
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observed no interference between A1 and A2 on the DNase I footprinting gels, and these 
two sites appear to have no interaction when VraR binds to the promoter. 
The EMSA assays indicated that M1 significantly decreased the binding affinity of 
VraR/VraR~P at A2, while mutations in A1 had no effect. VraR~P had very low binding 
affinities to the short fragments (A1a, A1b, and A1c) derived from A1, and VraR did not 
bind even at VraR concentrations as high as 40µM. Mutations in A1a and A1b had no 
effect, perhaps suggesting that phosphorylated VraR had the ability to bind to A1, but the 
binding was weak and may not have been very specific, which was consistent with the 
findings from the DNase I footprinting assays that mutations in A1 had little or no effect 
on the VraR~P protection pattern. 
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CHAPTER	THREE:	DETERMINATION	OF	VRAR	BINDING	ACTIVITY	AT	
FMTA	PROMOTER	IN	VIVO	 	
3.1 Introduction 
Previous in vitro results indicated that M1 significantly influenced VraR binding 
activity at A2, while mutations in A1 had little effect. To further elucidate the binding 
activity of VraR, I performed in vivo experiments to confirm the effect of the mutants M1, 
M4, and M6, which had some effect on VraR binding to PfmtA, on the interaction 
between VraR and PfmtA. Because the mutations in A1 did not affect the expression of 
fmtA relative to the wild type, I wanted to determine if the deletion of the entire A1 site 
from PfmtA would affect expression under oxacillin treatment.  
Francis et al. (2000) constructed a novel vector (lux plasmid/pXEN1) by adding a 
modified luxABCDE cassette (genes required for the expression of bioluminescent signals) 
to the pMK4 plasmid. This vector normally does not express bioluminescent signals due 
to the lack of a promoter region, but the restriction sites in the plasmid allow the addition 
of foreign promoters. The effectiveness of inserted foreign promoters could be easily 
determined by measuring the intensity of the bioluminescent signals. I constructed lux 
fusion plasmids by inserting PfmtA and mutants into the lux plasmid to test the differences 
in in vivo expression caused by the mutations. 
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An fmtA complementary strain had previously been produced in our lab. The fmtA 
gene was deleted from the genome of the RN4220 strain of S. aureus, and the loss of 
FmtA in vivo was complemented by a fusion plasmid constructed by inserting the fmtA 
gene and its 450-bp promoter region into a pMK4 expression vector. Modifications to 
PfmtA to explore its features were easily made, and the data from in vivo experiments 
reflected the true behavior of VraR more directly.  
3.2 Materials and Methods 
3.2.1 Bioluminescence expression assay and the construction of luxABCDE fusion strains with 
derivatives of the PfmtA region  
The regions of PfmtA and its mutants from -498 to +42 were amplified from 
pSTBlue-1 vectors containing the fmtA promoter (-498 to +42) or its mutants by primers 
containing EcoRI and BamHI restriction sites at their 5’ ends (DirFmtAP 5’- 
gccgaattcGAGAACCAATGCTAGAAGGATC and RevFmtAPr 
5’-gccggatccTACACACGCATGTATAACTAGT, respectively) and ligated into the 
pXEN1 vector by T4 DNA ligase (NEB). Both the PfmtA fragment and the pXEN1 vector 
were double-digested with EcoRI and BamHI (NEB) and purified using the QIAquick 
Gel Extraction Kit (Qiagen) before ligation. The plasmids were transformed into 
NovaBlue cells by heat shock (42 °C, 1 min) and into RN4220 by electroporation (2 kV, 
2.5 ms) using a Micropulser (Bio-Rad). Positive colonies were confirmed by plasmid 
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sequencing. The M1, M4, and M6 mutants of the fmtA promoter were produced, as 
described in Chapter 2.   
For the bioluminescence expression assay, 200 µL of an overnight culture of each 
target strain were added to 20 mL of TSB medium and incubated at 37 °C and 200 rpm to 
an OD600nm of approximately 0.4. Two 5-mL aliquots of the culture were then prepared, 
one received 10 µg/mL oxacillin and the other served as a control and both were 
incubated at 37 °C and 200 rpm for 30 min. At least three replicates of 300-µL aliquots 
from each sample were added to an opaque 96-well plate, and the bioluminescent signal 
was measured by a Synergy H4 plate reader with integral measurement for 100 ms at a 
luminescence height of 1 mm. 
3.2.2 Deletion of target fragments in pXEN1 containing the fmtA promoter  
All methods for deleting DNA fragments in plasmids in this study were modified 
from Pérez-Pinera et al. (2006) (Figure 3.1). To delete the entire A1 site (-380 to -326), 
the deletion-primers DirPfmtAA1de2 and RevPfmtAA1de2 containing NdeI restriction 
sites at their 5’ ends (Table 3.1) were used to amplify the plasmid but delete the target 
fragment. The PCR used 10 pg of plasmid template (pSTBlue-1 containing the fmtA 
promoter at -498 to +42), 2.5 U PfuTurbo DNA polymerase, 1X PfuTurbo buffer, 0.3 mM 
dNTPs, and 0.4 µM of each primer in a 50-µL reaction. The amplification product was 
gel-extracted and digested with DpnI and NdeI. The digested product was gel-purified 
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again and then ligated into pSTBlue-1 by T4 DNA ligase at 22 °C for 20 min. The 
plasmids, referred to as PfmtAA1-::pSTBlue-1, were then transformed by heat shock 
(42 °C, 2 min) into NovaBlue competent cells that were grown on LB plates containing 
50 µg/mL ampicillin. Deletion was confirmed by plasmid sequencing. 
        
 
 
 
 
 
Figure 3.1 Schematic diagram to illustrate the how the primers were designed 
containing the sequence of the restriction enzyme at the 5' end and with the 3' end 
oriented so that the polymerase will amplify the entire plasmid,but notthe region to 
be deleted (Pérez-Pinera et al. 2006). 5’-GGAATTCC represents the selection of 
restriction enzyme sites at the 5’end of designed primers and this is absentin the 
plasmid.  
As the result, the target region is replaced by selected restriction enzyme sites or 
removed from the plasmid if no restriction enzyme sites are selected. 
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The region of PfmtA (-498 to +42) containing the A1 deletion (-380 to -326 deleted) 
was amplified from the above plasmid by primers containing EcoRI and BamHI 
restriction sites at their 5’ ends (DirFmtAP 5’- 
gccgaattcGAGAACCAATGCTAGAAGGATC and RevFmtAPr 
5’-gccggatccTACACACGCATGTATAACTAGT, respectively) and ligated into the 
pXEN1 vector by T4 DNA ligase (NEB). Both the PfmtA fragment and the pXEN1 vector 
were double-digested with EcoRI and BamHI (NEB) and purified using the QIAquick 
Gel Extraction Kit (Qiagen) before ligation. The plasmids were transformed into 
NovaBlue cells by heat shock (42 °C, 1 min) and into RN4220 by electroporation (2 kV, 
2.5 ms) using a Micropulser (Bio-Rad). Positive colonies were confirmed by plasmid 
sequencing.  
3.2.3 Deletion/mutation of target fragments of the fmtA promoter in pMK4 containing fmtA and 
its promoter region  
3.2.3.1 Single-site mutagenesis of pMK4 containing fmtA and its promoter 
Mutant M1 (-233A/AA) of the VraR A2 binding site was generated in pMK4 
containing fmtA and its promoter using the QuikChangeTM Site-Directed Mutagenesis Kit 
(Stratagene). Two primers, 5’ - 
GCGACTTTAGTAATGATGTCTTAAAAAATTTAAAGGC and  
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5’ – GCCTTTAAATTTTTTAAGACATCATTACTAAAGTCGC, were used to 
PCR-amplify pMK4 plasmids containing fmtA and its promoter region (-450 to -1). The 
products were digested with DpnI and then transformed by heat shock into NovaBlue 
competent cells that were grown on LB plates containing 50 µg/mL ampicillin. Mutation 
was confirmed by plasmid sequencing. The plasmids containing the expected mutation 
were transformed into the RN4220 ΔfmtA strain by electroporation. Colonies were picked 
from TSB plates supplied with 20 µg/mL chloramphenicol, and the mutations were 
confirmed by plasmid sequencing. 
3.2.3.2 Deletion of target fragments in pMK4 containing fmtA and its promoter 
To delete the entire A1 site (-380 to -326), the deletion primers DirPfmtAA1del and 
RevPfmtAA1del with SmaI restriction sites at their 5’ ends (Table 3.1) were used to 
amplify the plasmid but delete the target fragment. The PCR used 2 pg of plasmid 
template (pMK4 containing fmtA and its promoter), 2.5 U PfuTurbo DNA polymerase, 1X 
PfuTurbo buffer, 0.3 mM dNTPs, and 0.4 µM of each primer in a 50-µL reaction. The 
amplification product was gel-extracted and digested with DpnI and SmaI. The digested 
product was gel-purified again and then ligated with T4 DNA ligase at 22 °C for 20 min. 
(An alternative method is to digest the PCR product with DpnI only and mix equal 
volumes of End conversion buffer provided with the pSTBlue-1 vector and the 
gel-extracted DNA at 22 °C for 15 min and then add T4 DNA ligase at 22 °C for 20 min.) 
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The plasmids were transformed by heat shock (42 °C, 2 min) into NovaBlue competent 
cells that were grown on LB plates containing 50 µg/mL ampicillin. Deletion was 
confirmed by plasmid sequencing. The plasmids containing the expected deletion were 
then transformed into the RN4220 ΔfmtA strain by electroporation. Colonies were picked 
from TSB plates supplied with 20 µg/mL chloramphenicol, and the deletions were 
confirmed by plasmid sequencing.  
 
Table 3.1 Primers used to generate mutations (deletion/replacement of targeted 
sequences in PfmtA) in plasmids. Letters highlighted in red represent restriction 
sites added to the 5’ end of each primer to replace the targeted sequences with the 
restriction sites. 
Primer Primer sequence Mutant generated 
DirPfmtAA1del 5’-TCCCCCGGGTAAAAAATACAAATG
TTATG 
Deletion of A1 site in 
pMK4 
RevPfmtAA1del 5’-TCCCCCGGGATCGTTCAACTAATTA
TAT 
DirPfmtAA1de2 5’-GGGAATTCCATATGTAAAAAATACA
AATGTTATG 
Deletion of A1 site 
in pXEN1 
RevPfmtAA1de2 5’-GGGAATTCCATATGATCGTTCAACT
AATTATAT 
 
3.2.4 Isolation of total RNA from S. aureus strains 
One hundred and sixty microliters of overnight cultures of each target strain were 
added to 16 mL of TSB medium and incubated at 37 °C and 200 rpm in a 50-mL Falcon 
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tube to an OD600nm of approximately 0.4. Two 5-mL aliquots of the cultures were then 
prepared, one received 10 µg/mL oxacillin and the other served as a control and both 
were incubated for 30 min at 37 °C and 200 rpm. Total RNA was isolated from the S. 
aureus strains using the RNeasy Mini Kit (Qiagen), with minor modifications of the 
supplied protocol. One milliliter of the S. aureus cultures were vigorously mixed with 2 
mL of RNAprotect Bacteria Reagent (Qiagen) for 10 s and centrifuged at 5000 X g for 10 
min at 4 °C after resting for 5 min. The pellets were resuspended in 200 µL of buffer 
containing 180 µL of TE buffer (30 mM Tris and 1 mM EDTA, pH 8.0) and 20 µL of 
lysostaphin (1.25 mg/mL) and incubated at room temperature for 30 min. One microliter 
of proteinase K (NEB) was added, and the suspensions were incubated at room 
temperature for 30 min, then 700 µL of buffer RLT were added, and the suspensions were 
vortexed for 15 s. The samples were transferred to 2-mL tubes containing glass beads and 
vortexed vigorously three times for 20 s with 20-s rests. The samples were centrifuged at 
18 000 Χ g for 1 min, and 700 µL of the supernatants were transferred to new 2-mL tubes 
and mixed with 470 µL of 100% ethanol. The samples were loaded onto RNeasy Mini 
spin columns and centrifuged at 8000 X g for 20 s and then washed once with 350 µL of 
buffer RW1 and twice with 500 µL of buffer RPE. The samples were recentrifuged for 1 
min to remove all possible solution residues in the column. Total RNA was eluted with 50 
43 
 
µL of distilled water, and 5000 ng of the RNA were digested with 4 U DNase I in a 50-µL 
reaction for 20 min at 37 °C. The DNase I was inactivated at 75 °C for 10 min. 
3.2.5 qRT-PCR to investigate the level of fmtA transcription in S. aureus RN4220 and its derived 
strains 
cDNA was synthesized using the High Capacity RNA-to-cDNA kit (Life 
Technologies) from 500 ng of total RNA digested with DNase I. For qRT-PCR, a 20-µL 
reaction was prepared containing 10 µL of SYBR SELECT Master Mix (Life 
Technologies), 0.25 µM each primer, and 25 ng of cDNA template. PCR reactions were 
performed on a Rotor-gene Q qRT-PCR cycler (Qiagen) under the following conditions: 
50 °C for 2 min; 95 °C for 10 min; 40 cycles of 95 °C for 15 s, 60 °C for 30 s, and 72 °C 
for 30 s; and a final extension step at 72 °C for 10 min (Zhao et al. 2012). Two primers 
were designed to specifically amplify the targeted fragment on fmtA: FmtADir 5’ 
TGGTACGAAAAAGTATCCAGATG and FmtARev 5’ 
CCAAAGAATCCCCCGTTAAG. Specific primers were also designed targeting the 16s 
RNA gene: 16S-RNADir 5’ GCTAAGTGTTAGGGGGTTTCC and 16S-RNARev 5’ 
TTCAACCTTGCGGTCGTACT. 
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3.3 Results  
3.3.1 Bioluminescence assays 
pXEN1 plasmids with wild-type or mutant (M1, M4, and M6) PfmtA were referred 
to as lux fusion plasmids: PfmtA::lux, PfmtAM1::lux, PfmtAM4::lux, and PfmtAM6::lux, respectively. 
The RN4220 strains of S. aureus with the above plasmids were referred to as lux fusion 
strains: RN(PfmtA::lux), RN(PfmtAM1::lux), RN(PfmtAM4::lux), and RN(PfmtAM6::lux), 
respectively. RN4220 with the stock pXEN1 vector was referred to as RN(::lux). RN4220 
with pXEN1 with the A1-deleted PfmtA (the VraR binding-site A1 deleted from PfmtA) 
was referred to as RN(PfmtAA1-::lux). In the PfmtAA1-::lux plasmid, the A1 site was replaced 
by CATAATG. 
All lux fusion plasmids with wild-type or mutant PfmtA but without oxacillin 
treatment produced bioluminescent signals of similar strengths in RN4220 (Figure 3.2). 
The signal strengths for the above strains treated with oxacillin, except for 
RN(PfmtAM1::lux), were approximately 2-fold higher. The stronger signals suggested that 
M1 effectively caused the loss of up-regulation at the fmtA promoter by VraR upon 
oxacillin treatment, while M4 and M6 had no effect, consistent with the previous in vitro 
results. The average signals from RN4220 with M4 and M6 were slightly higher than 
those from RN4220 with wild-type PfmtA after oxacillin treatment, but this trend was not 
consistent for each trial (Figure 3.2). Different concentrations of oxacillin (10 ng/µL or 
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100 ng/µL) had little effect on the trend of signal change with or without oxacillin 
treatment (Figure 3.2). 
Mutant M1 of VraR binding-site A2 in PfmtA caused the loss of protection upon 
DNase I digestion in vitro and the loss of up-regulation of fmtA by oxacillin treatment in 
vivo. Mutations in A1 had a weak effect on VraR binding to PfmtA in vitro, but these 
mutations had no significant effect on the expression level of fmtA in vivo (Figure 3.2). I 
hypothesized that A1 may not be essential for VraR binding, or it may be a non-specific 
binding site. To determine the importance of A1 on the expression of fmtA regulated by 
VraR, I deleted A1 from PfmtA and determined its effect with the bioluminescence and 
qRT-PCR assays. 
 
 
 
 
 
 
 
 
 
Figure 3.2 Fold increase of bioluminescence signals obtained from lux fusion 
strains under different treatments (no oxacillin, 10ng/μL oxacillin, and 100ng/μL 
oxacillin). The bioluminescence signal obtained from RN(PfmtA::lux) under no 
oxacillin conditons was indexed to one. Bars indicate mean ± SD. The standard 
deviations were calculated from three independent experiments.  
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The strengths of the bioluminescent signals without oxacillin treatment were similar 
for the A1 deletion and RN4220 with the wild-type PfmtA, but the signals increased 1.77- 
and 1.85-fold, respectively, after oxacillin treatment (Figure 3.3). The patterns of 
expression in these two strains did not significantly differ. RN(PfmtAM1::lux) served as a 
control in these trials and provided results similar to those earlier in this study. 
3.3.2 qRT-PCR for the deletion of A1 in PfmtA 
Two mutated strains of RN4220 had previously been produced in our lab: RN4220 
ΔvraR strain (RN4220 Δ(vraR)) and RN4220 ΔvraS (RN4220 Δ(vraS)). The vraR and 
Figure 3.3 Fold increase of bioluminescence signals obtained from lux 
fusion strains. The bioluminescence signal obtained from RN(PfmtA::lux) 
under no oxacillin conditions was indexed to one. Bars indicate mean ± 
SD. The standard deviations were calculated from three independent 
experiments. Deletion of entire A1 site didn’t affect the bioluminescence 
signal expression in comparison to the wild type. 
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vraS genes were mutated in the genomes of these two strains, preventing the expression 
of the VraR and VraS proteins in vivo. qRT-PCR assays were conducted to investigate the 
effects of these mutations in vraR or vraS on fmtA expression in vivo (Figure 3.4a). The 
mutations had no effect on the levels of transcription of fmtA without oxacillin treatment. 
The level of transcription of fmtA was up-regulated 5.24-fold in the oxacillin-treated 
RN4220 wild-type but was not up-regulated in either of the oxacillin-treated mutated 
strains (Figure 3.4a). 
To investigate the role of A1 and A2 in fmtA expression, I performed qRT-PCR to 
determine the fmtA transcription levels with and without oxacillin treatment. The pMK4 
plasmids with fmtA and its wild-type promoter, M1, and the A1 deletion were referred to 
as pMK4 fusion plasmids: fmtA::pMK4, fmtAM1::pMK4, and fmtAA1-::pMK4, respectively. 
The RN4220 fmtA-mutated strains with the above plasmids were referred to as fmtA 
complementary strains: RNfmtA-(fmtA::pMK4), RNfmtA-(fmtAM1::pMK4), and 
RNfmtA-(fmtAA1-::pMK4), respectively. In the fmtAA1-::pMK4 plasmid, the A1 site was 
replaced by CCCGGG. 
The transcription of fmtA in the RNfmtA-(fmtAA1-::pMK4) strain increased 4.75-fold 
after oxacillin treatment, similar to the wild-type strain (Figure 3.4b). The expression of 
fmtA did not change significantly in the fmtA complementary strain containing M1 in 
PfmtA either with or without oxacillin treatment (Figure 3.4c). 
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a 
b 
c 
Figure 3.4 qRT-PCR results to investigate the fmtA transcription levels in different S. aureus 
strains. (a) Comparison of RN4220 and its vraR and vraS mutants. (b) Comparison of 
RN4220 complementary strain  and its A1-deletion mutant. (c) Comparison of RN4220 
complementary strain and its mutant M1. The fmtA transcription was normalized to 
housekeeping gene 16S-RNA gene. The fmtA transcription in RN4220 without oxacillin 
treatment was indexed to one in figure 3.4a and the fmtA transcription in 
RNfmtA-(fmtA::pMK4) without oxacillin treatment was indexed to one in figure 3.4b and c. 
Bars indicate mean ± SD. The standard deviations were calculated from three independent 
experiments. 
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3.4 Discussion 
The in vivo studies (bioluminescence and qRT-PCT assays) showed similar trends 
with the in vitro studies. The lux fusion strains with M4 and M6 responded similarly to 
oxacillin treatment as did the strain with wild-type PfmtA, and the increases in the levels 
of the bioluminescent signal and fmtA transcription in the qRT-PCR were near or higher 
than 2-fold, while strains with M1 did not respond to oxacillin treatment.  
As expected, the deletion of A1 did not significantly change the level of fmtA 
expression in the A1-deleted strain relative to the wild-type strain in both experiments, 
suggesting that A1 was not essential to fmtA up-regulation under oxacillin treatment. A1 
may thus not be involved in fmtA regulation or is not a major regulation site. VraR 
binding-site A2 was the major binding site in PfmtA. With oxacillin treatment,  
phosphorylated VraR could bind to the two conserved motifs in A2 of PfmtA and 
up-regulate fmtA expression to compromise the effect of oxacillin. 
The study of the RN4220 ΔvraR and ΔvraS mutants confirmed that fmtA belonged 
to the VraSR regulon family. Both VraR and VraS were essential for the up-regulation of 
fmtA expression in response to oxacillin-induced environmental stress. 
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CHAPTER FOUR: DETERMINATION OF THE TRANSCRIPTION 
START SITE OF FMTA 
4.1 Introduction 
The transcription start site (TSS) of fmtA had previously been determined to be 
-156T by in vitro runoff transcription assays (Zhao et al. 2012). The RNA polymerase 
(RNAP) used in the assays, however, was from E. coli, not S. aureus. The differences 
between the RNAPs from E. coli and S. aureus prompted us to confirm if -156T was the 
true or only TSS of fmtA in S. aureus.  
4.2 Materials and Methods 
4.2.1 Determination of the TSS of fmtA by FirstChoiceTM RLM-RACE Kit 
Total RNA was isolated from S. aureus RN4220 using the RNeasy Mini Kit 
(Qiagen) as described in Chapter 3. FirstChoiceTM RLM-RACE Kit (Ambion) was used 
to determine the TSS of fmtA. The protocol in this study was slightly modified from the 
standard procedure provided with the kit.  
RNA Ligase Mediated Rapid Amplification of cDNA Ends (RLM-RACE) is a 
PCR-based technique used to determin the TSS in this study (Figure 4.1). The supplied 
adapter containing sequences corresponding to two nested sense primers is ligated to the 
5’ end of mRNA. A random-primed reverse transcription procedure and followed PCR 
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amplification by using these two antisense primers specific to the target gene provide 
DNA fragments with high specificity and the TSSs will be determined by subsequent 
DNA sequencing.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Total RNA treated with DNase I was precipitated with 2.5 volumes of isopropanol 
and 70% ethanol and then resuspended in 11 µL of distilled water. Ten-microliter 
reactions were prepared with 10 µg of RNA, 1 µL of TAP buffer, and 1 µL of TAP and 
Figure 4.1 A schematic procedure of RLM-RACE in this study to determine the 
transcription start site of fmtA. TSS: Transcription start site. Adapter: a 45 base 
RNA adapter oligonucleotide, provided with the kit to ligate to the mRNA, nested 
two sense primer sequences facilitating following PCR amplification. Vector: 
pSTBlue-1 in this study. Dark-blue horizontal bars: RNA fragments. Light-blue 
horizontal bars: DNA fragments. 
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then incubated at 37 °C for 1 h. A 10-µL reaction was prepared with 5 µL of TAP-treated 
RNA, 1 µL of 5’ RACE adapter, 1 µL of RNA ligase buffer, and 2 µL of T4 RNA ligase 
(2.5 U/µL) and incubated at 37 °C for 1 h. A 20-µL reverse-transcription reaction was 
prepared with 2 µL of ligated RNA, 4 µL of dNTPs, 2 µL of random decamers, 1 µL of 
RNase inhibitor, 1 µL of RT buffer, and 1 µL of M-MLV Reverse Transcriptase and 
incubated at 42 °C for 1 h. A manually designed primer, PfmtAouterRev 
5’-AACCTTTTCCTTATTACGAT, and the 5' RACE Outer Primer provided with the kit 
were used for the PCR amplification. A manually designed primer, PfmtAinnerRev 
5’-TGTGTCTTCGTCTGTAATCG, and the 5' RACE Inner Primer provided with the kit 
were used for the secondary amplification of the first PCR product. The PCR product was 
inserted into the pSTBlue-1 vector that was then transformed into NovaBlue cells, as 
described in the manual, and colonies were picked and analyzed by plasmid sequencing. 
4.2.2 Determination of the TSS of fmtA by primer extension 
Total RNA was isolated from the target S. aureus strains, and 30-100 µg were 
dissolved in 60 µL of hybridization buffer (40 mM PIPES, pH 6.4, 1 mM EDTA, 0.4 M 
NaCL, and 80% (v/v) formamide) at 65 °C. For each strain, 0.5 pmol of primer 
RevFmtAEx1 5’- AATGATAAATAATAGTACACACGC or of primer RevFmtAEx2 
5’- AACCTAGATGCCTAATAATACAAC labeled with [γ-32P]ATP (3000 Ci/mmol) was 
added, and the solution was incubated at 95 °C for 5 min for denaturation and then at 
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45 °C for 4 h for annealing. The samples were precipitated with ethanol and dissolved in 
9 µL of distilled water, and the following components were added: 0.75 µL of RNasin, 
0.75 µL of dNTPs (20 mM), and 0.75 µL of D-actinomycin (4 mg/mL). After incubation 
at 42 °C for 2 min, 1.3 µL (13 U) of AMV-RT were added, and the mixture was incubated 
at 42 °C for 2 h. The reaction was terminated by adding 25 µL of stop buffer (100 µg/mL 
RNase A and 30 µg/mL herring sperm DNA in TE buffer, pH 8.0) and incubating at 37 °C 
for 30 min. After ethanol precipitation, the samples were dissolved in 7 µL of loading 
buffer (10 mM NaOH, 1 mM EDTA, 0.05% xylene cyanol and bromophenol blue, and 80% 
formamide) and electrophoresed on an 8% polyacrylamide sequencing gel. The gel was 
dried under vacuum and exposed to a phosphor screen for 18-24 h. A phiX 174 
DNA/HinfI dephosphorylated marker (Promega) labeled with [γ-32P]ATP (3000 Ci/mmol) 
was used to indicate the position of the RNA transcription product of fmtA. The 
RevFmtAEx2 primer labeled with [γ-32P]ATP (3000 Ci/mmol) was also used in the 
following 10-µL PCR reactions to generate a more accurate marker: 1µL of end-labeled 
primer, 0.5 µL of Therminator DNA polymerase, 50 nM dNTPs, 1.9 µM acyGTP or 
acyCTP, and 300-600 ng of template DNA (plasmid containing the fmtA promoter). The 
cycling program was: denaturation at 95 °C for 2 min; 30 cycles of 95 °C for 20 s, 55 °C 
for 30 s, and 72 °C for 20 s; and a final extension step at 72 °C for 5 min 
(primer-extension protocol modified from Harraqhy et al. 2005). 
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4.2.3	Determination	of	the	TSS	of	fmtA	in	the	fmtA	complementary	strain	
4.2.3.1 Single-site mutation of pMK4 containing fmtA and its promoter 
The predicted TSSs G-157, T-156, A-53, and A-52 were mutated (G to T, T to G, 
and A to C, respectively) in pMK4 containing fmtA and its promoter region using the 
QuikChangeTM Site-Directed Mutagenesis Kit (Stratagene).  
Primers containing targeted mutations were used to PCR-amplify pMK4 containing 
the fmtA gene and its promoter region (Table 4.1). The plasmids were digested with DpnI 
and then transformed by heat shock into NovaBlue competent cells that were grown on 
LB plates containing 50 µg/mL ampicillin. Mutation was confirmed by plasmid 
sequencing. The plasmids containing the expected mutated sites were then transformed 
into the RN4220 ΔfmtA strain by electroporation. Colonies were picked from TSB plates 
supplied with 20 µg/mL chloramphenicol, and the mutations were confirmed by plasmid 
sequencing. 
Table 4.1 Primers used to generate mutations in pMK4 containing the fmtA gene 
and its promoter region (-450 to -1). 
Primer Primer sequence Mutation site 
DirFmtAG342T 5’- 
AGGTATAATTAATTTTTTTGTATAGA
TAACAT 
-157G/T 
RevFmtAG342T 5’- 
ATGTTATCTATACAAAAAAATTAATT
ATACCT 
FmtA T+1G Dir 5’ - 
GGTATAATTAATTTTGGTGTATAGAT
AACAT 
-156T/G 
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FmtA T+1G Rev 5’ - 
ATGTTATCTATACACCAAAATTAATT
ATACCT 
DirPfmtAA446C 5’- 
GGCATCTAGGTTCACATTTTTAACG
ATTT 
-53A/C 
RevPfmtAA446C 5’- 
AAATCGTTAAAAATGTGAACCTAGA
TGCC 
DirFmtAA447C 5’- 
GGCATCTAGGTTCAACTTTTTAACG
ATTT 
-52A/C 
RevFmtAA447C 5’- 
AAATCGTTAAAAAGTTGAACCTAG
ATGCC 
DirG342-10D 5’ 
-TCCCCCGGGATTTTGTTGTATAGAT
AAC 
Deletion of the 
-10 region of 
-157G 
RevG342-10D 5’ - 
TCCCCCGGGCTTATCACTTTGTATA
AAT 
RevG304-10del 5’ - GCCTTTAAATTTTTTAAGAC Deletion of the 
-10 region of 
-195G 
DirG304-10del 5’ - TCGAGTGATTTATACAAAGT 
4.2.3.2 Deletion/replacement of the -10 regions of predicted TSSs in pMK4 containing fmtA and 
its promoter 
The -10 region (TATAAT, upstream from -170T to -165T) (Figure 1.2) of the 
predicted TSS -157G was deleted from pMK4 containing fmtA and its promoter. And the 
-10 region of -195G (TAATAT, upstream from -207T to -202T) was deleted from the 
above plasmid. Primers used are listed in Table 4.1.  
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PCR-amplified plasmids were digested with DpnI and then gel-extracted. An equal 
volume of the End conversion buffer provided with the pSTBlue-1 vector was added, and 
the solution was incubated at 22 °C for 15 min. One microliter of T4 DNA ligase was 
added and incubated at 22 °C for 20 min. Ligated plasmids were transformed by heat 
shock (42 °C, 2 min) into NovaBlue competent cells that were grown on LB plates 
containing 50 µg/mL ampicillin. Mutation was confirmed by plasmid sequencing. The 
plasmids containing the expected mutated sites were then transformed into the RN4220 
ΔfmtA strain by electroporation. Colonies were picked from TSB plates supplied with 20 
µg/mL chloramphenicol, and the mutations were confirmed by plasmid sequencing. 
4.3 Results and Discussion 
4.3.1 Determination of the TSS of fmtA 
Adapters (provided with the FirstChoice® RLM-RACE Kit) were attached to the 5’ 
ends of the transcripts of fmtA in RN4220, and PCR reactions were performed to identify 
the DNA fragments capable of being amplified with specific primers. Two bands with the 
expected size were observed on an agarose gel (Figure 4.2). Each band was isolated and 
sequenced, and three potential TSSs were found: -157G, -53A, and -52A.  
Four single-nucleotide mutants in these three putative TSSs, together with the 
putative TSS, -156T, were generated to test the effect of fmtA in the fmtA complementary 
strain on transcription level (Figure 4.3). -156T was the previously predicted TSS (Zhao 
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et al. 2012). The fmtA complementary strain and the four mutants were referred to as: 
RNfmtA-(fmtA::pMK4), RNfmtA-(fmtA-157G/T::pMK4), RNfmtA-(fmtA-53A/C::pMK4), 
RNfmtA-(fmtA-52A/C::pMK4), and RNfmtA-(fmtA-156T/G::pMK4), respectively.  
The -10 region of each putative TSS is located about 10 nucleotides upstream of the 
TSS and is essential for the recognition and binding of RNA polymerase. Both -157G and 
-156A shared the same -10 region (TATAAT, upstream from -170T to -165T), while the 
-10 region of -53A and -52A lacked a common feature of the -10 regions in bacteria: a 
high-T/A content. The -10 region of -157G was thus deleted in the fmtA complementary 
strain, which was then referred to as RNfmtA-(fmtA-157G-10del::pMK4). Here, the region from 
-171G to -163A (9bp long) was replaced by CCCGGGGGATCCCCCGGG (18bp long). 
A mutation at -157G or the deletion of its -10 region caused a significant decrease 
(~0.3-fold) in the level of fmtA transcription without oxacillin treatment relative to the 
wild-type fmtA complementary strain, but the other mutants did not significantly affect 
the transcription level. After oxacillin treatment, the fmtA transcription levels significantly 
increased (more than 2-fold) in all the above strains relative to the levels in the same 
strains without oxacillin treatment. The oxacillin-induced fmtA transcription level was 
similar to the fmtA expression in the wild-type fmtA complementary strain without 
oxacillin treatment (Figure 4.3) when the -10 region of -157G was deleted. 
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These observations indicated that -157G is likely to be the true TSS of fmtA without 
oxacillin treatment. The fmtA transcription level, however, was also up-regulated when 
treated with oxacillin, even though -157G or its -10 region was mutated, perhaps 
suggesting that another TSS, or multiple TSSs, of fmtA was responsible for the increase 
upon oxacillin treatment. 
4.3.2 Determination of the TSS of fmtA by primer extension 
I tested the possibility of other TSSs for fmtA by primer extension. Primer extension 
was conducted in fmtA in the RN4220 and fmtA complementary strains, with and without 
oxacillin treatment. Two TSSs were observed on a polyacrylamide gel: -195G and -157G. 
-157G was consistent with the TSS identified by the FirstChoice® RLM-RACE Kit. 
-195G was a new potential TSS. As predicted, transcription starting from -157G was not 
increased by oxacillin treatment, but transcription starting from -195G was significantly 
increased after oxacillin treatment (Figure 4.4). The band intensity from the fmtA 
complementary strain was much higher than that from RN4220, which indicated that the 
complementary strains had multiple copies of pMK4 fusion plasmids.  
Primer extension also provided additional evidence for previous results in this study. 
In the vraR-mutated RN4220 strain, -157G was the only TSS for fmtA, and no band was 
observed at the -195G position (Figure 4.5), suggesting that transcription starting from 
-195G was controlled by the VraSR two-component system upon oxacillin treatment. 
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fmtA had a basal level of transcription at -195G in RN4220 without oxacillin treatment, 
while no fmtA transcription products were produced by the same position in vraR-mutated 
RN4220 no matter with or without oxacillin treatment (Figure 4.4 and 4.5). This finding 
may indicate that VraR is the only regulatory factor responsible for the basal level of 
transcription starting from -195G in the absence of environmental stress.  
The level of fmtA transcription from -195G was much lower in the fmtA 
complementary strain containing M1 in PfmtA than in A1-deleted PfmtA, both with and 
without oxacillin treatment. This finding suggested that M1 in the VraR binding-site A2 
had a larger effect on fmtA transcription from -195G than did the deletion of VraR 
binding-site A1, in agreement with previous conclusions in this study (Figure 4.5). 
No transcription products were produced in the fmtA complementary strain where 
the -10 regions for both -157G and -195G had been deleted (Figure 4.6). Bands occurred 
at the regular -195 and -157 positions on the same polyacrylamide gel, but these bands 
had been produced by the genome, not the complementary plasmid, because PfmtA had 
not been deleted from the genome when the fmtA-mutated RN4220 was generated. This 
also explained why the band intensity at position -195 increased significantly under 
oxacillin treatment in the fmtA complementary strain containing M1 (Figure 4.5). 
I can conclude that fmtA transcription initiation occurs mainly at -157G in the 
absence of oxacillin treatment and is not affected by oxacillin treatment, perhaps 
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suggesting that neither VraR nor VraR~P have an effect on transcription starting from 
-157G. The transcription of fmtA starting from -195G maintains a basal level without 
oxacillin treatment, likely due to a basal level of VraR expression in the absence of 
environmental stress, and transcription initiation at this position is dramatically 
up-regulated with oxacillin treatment or in the presence of other cell-wall stressors. 
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Figure 4.2 Two bands containing the potential transcription start sites of fmtA were 
inserted to pSTBlue-1 vector for sequencing. Three potential transcription start 
sites were identified: –157G, -53A and –52A on the fmtA promoter region.  
 Figure 4.3 qRT-PCR results to investigate the effect on fmtA transcription level 
in fmtA complementary strain by single-site mutations/deletions. Single-site 
mutations on -156T, -53A, and -52A did not significantly change the fmtA 
expression in fmtA complementary strain. While, -157G/T or deletion of its -10 
region significantly decreased fmtA expression level under non-oxacillin 
condition, and it was observed that, after treated by oxacillin, fmtA expression 
significantly increased in these two mutation strains.  
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Figure 4.4 Primer extension experiments to determine the transcription start site of 
fmtA.  
Lane M represents ΦX174 DNA/HinfI Dephosphorylated ladder. Lane G/C 
represents G/C ladder prepared by 32p-ATP labeled primer RevFmtAEx2. 
Lane 1/3: transcription start site of fmtA in RN4220 without/with oxacillin 
treatment. Lane 2 was similar to lane 3, except primer RevFmtAEx1 was used 
instead of RevFmtAEx2. Lane 4/6: transcription start site of fmtA in fmtA 
complementary strain without/with oxacillin treatment. Lane 5 was similar to lane 
6, except primer RevFmtAEx1 was used instead of RevFmtAEx2. Two 
transcription start sites were observed on the gel: -157G and -195G. Lane 3 and 
lane 5 serve as the reference.  
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Figure 4.5 Primer extension experiments to determine the transcription start site of 
fmtA and VraR binding activity. G/C represents G/C ladder prepared by 32p-ATP 
labeled primer RevFmtAEx2. Lane 1/3/5: transcription start site of fmtA in 
RN4220 ΔvraR, fmtA complementary strain containing mutation M1 on PfmtA, 
and fmtA complementary strain containing A1-deleted PfmtA without oxacillin 
treatment. Lane 2/4/6: transcription start site of fmtA in RN4220 Δ(vraR), fmtA 
complementary strain containing M1 in the plasmid, and fmtA complementary 
strain containing A1-deleted PfmtA with oxacillin treatment. Positions of two 
putative transcription start sites -195G and -157G were indicated by green and red 
arrows, respectively.  
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Figure 4.6 Primer extension experiments to determine the transcription start site of 
fmtA. Lane 1/3: transcription start site of fmtA in fmtA complementary strain and fmtA 
complementary strain containing deletion of -10 regions for both -195G and -157G 
without oxacillin treatment. Lane 2/4: transcription start site of fmtA in fmtA 
complementary strain and fmtA complementary strain containing deletion of -10 
regions for both -195G and -157G with oxacillin treatment. Positions of two putative 
transcription start sites -195G and -157G were indicated by green and red arrows, 
respectively.  
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CHAPTER FIVE: INVESTIGATION OF VRAR BINDING ACTIVITY 
AT THE PROMOTERS OF MURZ, SGTB, AND PBP2  
5.1 Introduction 
More than 40 genes in S. aureus are considered members of the VraSR regulon and 
are up-regulated in the presence of vancomycin, oxacillin, and other cell-wall inhibitors 
(Bernal et al. 2010; Utaida et al.2003; Kuroda et al. 2003; McAleese et al. 2006; 
Muthaiyan et al. 2008; Sengupta et al. 2012). Of these genes, murZ, pbp2, and sgtB are 
clearly involved in the peptidoglycan biosynthesis pathway and are under the direct 
control by the VraSR two-component system (Sengupta et al. 2012). The in vivo evidence 
indicates that VraR is capable of binding to the promoter regions of these three genes with 
oxacillin induction (Sengupta et al. 2012). The positions of murZ, pbp2, and sgtB and 
their promoter regions are shown in Figure 5.1. 
murZ encodes UDP-N-acetylglucosamine enolpyruvyl transferase (MurZ) (also 
known as UDP-N-acetylglucosamine 1-carboxylvinyl transferase 2). MurZ transfers an 
enolpyruvyl group from phosphoenolpyruvate to UDP-N-acetylglucosamine to form 
UDP-N-acetylglucosamine enolpyruvate (a precursor to UDP-N-acetylmuramate, an 
essential component of the cell wall), which is the first committed step in peptidoglycan 
(PG) biosynthesis occurring at the cytoplasmic stage (Silver 2006; Du et al. 2000). The 
expression of MurZ is inducible by inhibitors of PG biosynthesis (Blake et al. 2009). 
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MurZ is the minor of two forms of UDP-N-acetylglucosamine enolpyruvyl transferase in 
S. aureus (MurA is the major form). The mutation of murZ reduces the PG content of the 
cell wall by only 3% (Du et al. 2000; Blake et al. 2009), perhaps suggesting that murZ 
mainly compensates for damage to the cell wall when stressed.  
SgtB (or MGT) is a putative monofunctional glucosyltransferase encoded by sgtB. 
The role of SgtB under cell-wall stress may become important in the final stages of 
peptidoglycan biosynthesis (Sengupta et al. 2012). The assembly of peptidoglycan 
polymers requires two types of enzymes: peptidoglycan glycosyltransferases (PGTs) and 
transpeptidases (TPs). PGTs catalyze the elongation of the carbohydrate chains, and TPs 
Figure 5.1 murZ, sgtB and pbp2 genes and their promoters in the genome of S. 
aureus strain Mu50. Blue arrowed lines indicate the range of the promoters and the 
direction of transcription (5’ – 3’). SAV1874 is the predicted sgtB gene. 
67 
 
catalyze cross-linking (Rebets et al. 2014; Lovering et al. 2008). S. aureus contains two 
monofunctional PGTs (SgtA and SgtB) and one bifunctional PGT (PBP2, with TP activity) 
(Rebets et al. 2014). Neither SgtA nor SgtB are essential in S. aureus, but SgtB is the only 
PGT that can compensate for the loss of the PGT domain in PBP2 in terms of the viability 
of S. aureus (Reed et al. 2011). PBP2, encoded by pbp2 (also known as pbpB), is a native 
penicillin-binding protein in MRSA and the only penicillin-binding protein having an 
N-terminal PTG domain and a C-terminal TP domain (Pinho et al. 2001). PBP2 catalyzes 
the cross-linking of carbohydrate chains (Rebets et al. 2014). Its transpeptidase activity 
can be compensated by PBP2A, a foreign-acquired PBP with low β-lactam affinity under 
β-lactam stress (Pinho et al. 2001). Both the transglycosylase domain of PBP2 and the 
transpeptidase domain of PBP2A, however, are important for cell-wall synthesis under 
β-lactam stress (Pinho et al. 2001; Pinho et al. 1998). Gardete et al. (2006) reported that 
the level of PBP2 expression could be rapidly sensed by the VraSR two-component 
system and that subsequent responses were made. The double roles of PBP2 as the trigger 
of the VraSR two-component system and as a member of the VraSR regulon highlight the 
importance of fully understanding the regulatory mechanism of pbp2. 
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5.2 Materials and Methods 
5.2.1 Determination of VraR binding activity at the promoters of murZ, pbp2, and sgtB by DNase 
I footprinting 
The primer pairs in Table 5.1 were used to PCR-amplify the promoter regions of 
murZ, pbp2, and sgtB, and the amplified fragments were inserted into the pSTBlue-1 
vector. Each promoter region was divided into two fragments, and each fragment was 
investigated by DNase I footprinting.  
 
Table 5.1 Primers used in the PCR amplification of the promoters of murZ, pbp2, and 
sgtB. Each promoter was divided into two short fragments, Seq1 and Seq2, and 
VraR/VraR~P binding activity at both fragments was investigated by DNase I 
footprinting. The A of the translation initiation codon (ATG) is referred to as +1 for 
murZ and sgtB, respectively. While the A of the translation start codon of pbp2 is 
+624, because pbp2 and recU share the same operon and the +1 position starts from 
the translation start codon of recU.   
Primer Primer sequence Amplified fragment 
DirPmurZ 5’ - ATTAAAGAGTTCGGTACTT -501 to -1, 
Full PmurZ RevPmurZ 5’ - ATCATTTATCTCCTTTGTCC 
DirPpbp2 5’ - GAGGACGCCTCCTACATT -539 to -1, 
Full Ppbp2 RevPpbp2 5’ - AAATTTCACCACACAAGT 
DirPsgtB 5’ - GAGAAATCGTTAAACAATTAC -365 to +2, 
Full PsgtB RevPsgtB 5’ - ATGCGTTTGCTCCTTCTT 
DirPmurZ 5’ - ATTAAAGAGTTCGGTACTT -501 to -252, 
Seq1 of PmurZ, RevPmurZseq1 5’ - TTTGTACGTAAACTTTTTTC 
DirPmurZseq2 5’ - TCGTAGAATTAAAACTAAAT -251 to -1, 
Seq2 of PmurZ RevPmuZ 5’ - ATCATTTATCTCCTTTGTCC 
DirPpbp2 5’ - GAGGACGCCTCCTACATT -539 to -270, 
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RevPpbp2seq1 5’ - ATCAGTAATTTTTATTTTTGAG Seq1 of Ppbp2 
DirPpbp2seq2 5’ - CATGATTTGACTTTTATAAC -269 to -1, 
Seq2 of Ppbp2 RevPpbp2 5’ - AAATTTCACCACACAAGT 
DirPsgtB 5’ - GAGAAATCGTTAAACAATTAC -365 to -203, 
Seq1 of PsgtB RevPsgtBseq1 5’ - TTGTAAAATAAAAGACCATC 
DirPsgtBseq2 5’ - AATATAACAATATTTGGCATG -202 to +2, 
Seq1 of PsgtB RevPsgtB 5’ - ATGCGTTTGCTCCTTCTT 
The primers pairs were used for the PCR amplification of seq1 of PmurZ, seq2 of 
PmurZ, seq1 of Ppbp2, seq2 of Ppbp2, seq1 of PsgtB, and seq2 of PsgtB. All amplified 
DNA fragments were purified using the QIAquick Gel Extraction Kit (Qiagen) and used 
as PCR templates in the DNase I footprinting assays. The 5’-end of the primer of interest 
(forward or reverse) was labeled with [γ-32P] ATP (3000 Ci/mmol) using 20 U of T4 
polynucleotide kinase (NEB) and used to amplify seq1-3 in a 20-µL reaction. Binding 
reactions were prepared in binding buffer (10 mM Tris-base, pH 7.5, 50 mM KCl, and 1 
mM DTT) supplemented with 5 mM MgCl2, 0.05% herring sperm DNA, and 2.5% 
glycerol. The end-labeled DNA (6-8 ng) was mixed with VraR/VraR~P at concentrations 
ranging from 0 to 40 μM. The binding reactions were incubated for 30 min at room 
temperature and then digested with DNase I (0.024 U/reaction) for 2 min. The digestion 
reactions were stopped by adding 50 μL of DNase I stop solution (1% SDS, 0.2 M NaCl, 
and 20 mM EDTA, pH 8.0). Digested DNA samples were extracted by phenol-chloroform 
and then precipitated with ethanol. Purified DNA was resuspended in loading dye 
containing 10 mM formamide, 1 mg/mL bromophenol blue, and 1 mg/mL xylene cyanol, 
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incubated at 95 °C for 5 min, and electrophoresed on an 8% polyacrylamide gel 
containing 7 M urea. The dried gels were exposed to a phosphor screen for 18-24 h and 
scanned using a Typhoon Trio+ variable-mode imager (GE HealthCare). The C and G 
sequencing reactions for these experiments were performed in 10-µL PCR reactions 
containing 1 µL of end-labeled primer, 0.5 µL of Therminator DNA polymerase, 50 nM 
dNTPs, 1.9 µM acyGTP or acyCTP, and 25 ng of template DNA (gel-purified seq1-3). 
5.2.2 Determination of the TSSs of murZ, pbp2, and sgtB by primer extension 
The primers in Table 5.2 were used in primer-extension experiments to investigate 
the TSSs of murZ, pbp2, and sgtB. Total RNA was isolated, and 100 µg were dissolved in 
60 µL of hybridization buffer (40 mM PIPES, pH 6.4, 1 mM EDTA, and 0.4 M NaCL, 80% 
(v/v) formamide) at 65 °C. For each reaction, 0.5 pmol of primer labeled with [γ-32P]ATP 
(3000 Ci/mmol) were added, and the solutions were incubated at 95 °C for 5 min for 
denaturation and at 45 °C for 4 h for annealing. The samples were precipitated with 
ethanol and dissolved in 9 µL of distilled water, and the following components were 
added: 3 µL 5xAMV-RT buffer, 0.75 µL of RNasin, 0.75 µL of dNTPs (20 mM), and 0.75 
µL of D-actinomycin (4 mg/mL). After incubation at 42 °C for 2 min, 1.3 µL (13 U) of 
AMV-RT were added, and the mixture was incubated at 42 °C for 2 h. The reaction was 
terminated by adding 25 µL of stop buffer (100 µg/mL RNase A and 30 µg/mL herring 
sperm DNA in TE buffer, pH 8.0) and then incubated at 37 °C for 30 min. After 
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precipitation with ethanol, the samples were dissolved in 7 µL of loading buffer (10 mM 
NaOH, 1 mM EDTA, 0.05% xylene cyanol and bromophenol blue, and 80% formamide) 
and were electrophoresed on an 8% polyacrylamide sequencing gel. The dried gels were 
exposed to a phosphor screen for 18-24 h and scanned using a Typhoon Trio+ 
variable-mode imager (GE HealthCare). A phiX 174 DNA/HinfI dephosphorylated 
marker labeled with [γ-32P]ATP (3000 Ci/mmol) was used to indicate the position of the 
RNA transcription products of fmtA. The primer RevFmtAEx2 labeled with [γ-32P]ATP 
(3000 Ci/mmol) was also used in the 10-µL PCR reaction below to generate a more 
accurate marker: 1 µL of end-labeled primer, 0.5 µL of Therminator DNA polymerase, 50 
nM dNTPs, 1.9 µM acyGTP or acyCTP, and 300-600 ng of template DNA (plasmid 
containing the fmtA promoter). The cycling program was: initial denaturation at 95 °C for 
2 min; 30 cycles of 95 °C for 20 s, 55 °C for 30 s, and 72 °C for 20 s; and a final 
extension step at 72 °C for 5 min. 
 
Table 5.2 Primers used in the primer-extension experiments to investigate the TSSs of 
murZ, pbp2, and sgtB. 
Primer Primer sequence Target gene 
RevMurZex1 5’ - TTAGTGTGCGTCCACCTC TSS of murZ 
RevSgtBex1 5’ - GGTTTGCCAACTGGTTGAT TSS of sgtB 
RevPbp2ex1 5’ - GATAAAACGTATTTGAATGTTCG TSS of pbp2 
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5.3 Results and Discussion 
5.3.1 Investigation of VraR binding sites in PmurZ, PsgtB, and Ppbp2 
The DNase I footprinting assays identified a VraR/VraR~P-protected region on 
Seq2 of PmurZ on both the top and bottom strands: 5’ - 
GTTGAataaTCAGACTttAGACCATGGTCAAGTGGGGAAGAACAGCA (top-strand 
sequence) (Figure 5.2a and 5.2b). The underlined sequence was protected by VraR~P only. 
Two putative VraR binding motifs (highlighted in red and green) were found in this site. 
They were highly conserved with the VraR binding motifs identified in the vraSR 
promoter (Belcheva et al. 2009) and the fmtA promoter in the present study.  
A VraR/VraR~P-protected region was identified on Seq2 of PsgtB on both the top 
and bottom strands: 5’ - 
GTAAGTATGATGGCGTATACGATTGTAAGCCCTTGGACTGATTTTCCCAAAAAG
TGTAGCC (top-strand sequence). The underlined sequence was protected by VraR~P 
only (Figure 5.2c and 5.2d). No highly conserved VraR binding motifs were found.  
Only two regions protected by VraR~P were found on Seq1 and Seq2 of Ppbp2. The 
Seq1 region was 
5’-CGATGAAAATACTTTTAATCTAATAAAATCATTTAAATCAAATACACCTCTGC
TGATTAA (top-strand sequence) on both the top and bottom strands (Figure 5.2e and 
5.2f). The Seq2 region was 
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5’-ATCACGTTAAAATAAGCTTTGGTGTATTGTGTCTTTCGCATTTATACTAATTTA
AGTTTGGTGTTTC (top-strand sequence) on both the top and bottom strands (Figure 
5.2g and 5.2h). No highly conserved VraR binding motifs were found in these two 
regions. 
5.3.2 The TSSs of murZ, sgtB, and pbp2 
Primer extension assays were performed to determine the TSSs in murZ, sgtB, and 
pbp2 in RN4220, both with and without oxacillin treatment (Figure 5.3).  
Two potential TSSs of murZ were identified (Appendix Figure 2a). One (-146G) 
had an increased band intensity upon oxacillin treatment, and the intensity of the other 
band (-42A) changed little (Figure 5.3). The conserved VraR binding motifs in PmurZ 
may indicate that murZ has a similar VraR binding activity at its promoter region and a 
similar mechanism of transcription initiation (one of the two TSSs (-146G) being 
responsible for the reaction to oxacillin treatment, and the other (-40G) maintaining the 
basal level of gene transcription). 
Only one TSS for sgtB (-38G) was found (Appendix Figure 2b), and the 
transcription level increased with oxacillin treatment (Figure 5.3). 
At least four TSSs (-105T, -30G, +87T, and +89G) of pbp2 were identified 
(Appendix Figure 2c), three of which (-30G, +87T, and +89G) had significantly increased 
levels of transcription with oxacillin treatment (Figure 5.3). The recU gene is located 
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upstream of pbp2 in the same operon. Nucleotide position +1 refers to the A of the 
translation start codon (ATG) of recU, and the A of the translation start codon (ATG) of 
pbp2 is located at +624. recU and pbp2 share a 4-bp overlap, ATGA, which includes the 
translation stop codon TGA of recU and the translation start codon ATG of pbp2. Three 
TSSs for pbp2 have been identified in the S. aureus COL strain: -105T, -30G, and +551A 
(Pinho et al. 1998). Two of these, -105T and -30G, were also identified in our study. I did 
not find the TSS at +551A identified by Pinho et al. (1998) because it was outside the 
range of the primer used. +87T and +89G were not observed by Pinho et al. (1998), 
perhaps because the transcription products starting from these two sites were due to 
induction by oxacillin. More TSSs for pbp2 may be identified in the recU gene upon 
oxacillin treatment. 
The identification of the precise nucleotides for each potential TSS was difficult due 
to the size of the gels in the primer-extension assays and the limitation of the phiX 174 
DNA/HinfI dephosphorylated ladder. Primers closer to the currently identified TSSs for 
each gene should be designed to verify our results. 
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Figure 5.2a Investigation of VraR/VraR~P binding activity on the top strand of 
PmurZ Seq2 by the DNase I footprinting assay. The region protected by 
unphosphorylated VraR is indicated by the green box and arrowed line. VraR~P 
protected sequence is indicated by the red box and arrowed line. Arrow direction 
represents sequence direction from 5’ to 3’ on the top strand. Numbers represent 
the start and end nucleotides of the protected region in the top strand of PmurZ.  
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Figure 5.2b Investigation of VraR/VraR~P binding activity on the bottom strand 
of PmurZ Seq2 by the DNase I footprinting assay. The region protected by 
unphosphorylated VraR is indicated by the green box and arrowed line. VraR~P 
protected sequence is indicated by the red box and arrowed line. Arrow direction 
represents sequence direction from 5’ to 3’ on the top strand. Numbers represent 
the start and end nucleotides of the protected region in the top strand of PmurZ.  
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Figure 5.2c Investigation of VraR/VraR~P binding activity on the top strand of 
PsgtB Seq2 by DNase I footprinting assay. The region protected by 
unphosphorylated VraR is indicated by the green box and arrowed line. VraR~P 
protected sequence is indicated by thered box and arrowed line. Arrow direction 
represents sequence direction from 5’ to 3’ on the top strand. Numbers represent 
the start and end nucleotides of the protected region in the top strand of PsgtB.  
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Figure 5.2d Investigation of VraR/VraR~P binding activity on the bottom strand 
of PsgtB Seq2 by DNase I footprinting assay. The region protected by 
unphosphorylated VraR is indicated by the green box and arrowed line. VraR~P 
protected sequence is indicated by the red box and arrowed line. Arrow direction 
represents sequence direction from 5’ to 3’ on the top strand. Numbers represent 
the start and end nucleotides of the protected region in the top strand of PsgtB.  
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Figure 5.2e Investigation of VraR/VraR~P binding activity on the top strand of 
Ppbp2 Seq1 by DNase I footprinting assay. VraR~P protected region is indicated by 
the red box and arrowed line. Arrow direction represents sequence direction from 5’ 
to 3’ on the top strand. Numbers represent the start and end nucleotides of the 
protected region in the top strand of Ppbp2.  
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Figure 5.2f Investigation of VraR/VraR~P binding activity on the bottom strand 
of Ppbp2 Seq1 by DNase I footprinting assay. VraR~P protected region is 
indicated by the red box and arrowed line. Arrow direction represents sequence 
direction from 5’ to 3’ on the top strand. Numbers represent the start and end 
nucleotides of the protected region in the top strand of Ppbp2.  
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Figure 5.2g Investigation of VraR/VraR~P binding activity on the top strand of 
Ppbp2 Seq2 by DNase I footprinting assay. VraR~P protected region is indicated by 
the red box and arrowed line. Arrow direction represents sequence direction from 
5’ to 3’ on the top strand. Numbers represent the start and end nucleotides of the 
protected region in the top strand of Ppbp2.  
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Figure 5.2h Investigation of VraR/VraR~P binding activity on the bottom strand of 
Ppbp2 Seq2 by DNase I footprinting assay. VraR~P protected region is indicated by 
the red box and arrowed line. Arrow direction represents sequence direction from 5’ 
to 3’ on the top strand. Numbers represent the start and end nucleotides of the 
protected region in the top strand of Ppbp2.  
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Figure 5.3 Primer extension experiments to determine the transcription start sites 
of murZ, sgtB and pbp2. M represents ΦX174 DNA/HinfI Dephosphorylated 
ladder. Lane 1, 5. 7, 9: transcription start sites of fmtA, murZ, sgtB and pbp2 in 
RN4220 without oxacillin presence. Lane 2, 6, 8, 10: transcription start sites of 
fmtA, murZ, sgtB and pbp2 in RN4220 in the presence of oxacillin. Lane 3/4: 
transcription start site of fmtA in PC1839 (RN4220 sarA mutation strain) 
without/with oxacillin. Red/green boxes indicate potential transcription start sites 
which are/not up-regulated in the presence of oxacillin.  
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CHAPTER SIX: CONCLUSIONS AND PERSPECTIVES 
Previous work has shown that the VraSR two-component system is able to sense 
damage on the cell wall and to coordinate a rapid response, including the upregulation of 
the transcription of a set of genes, to enhance the resistance to peptidoglycan inhibitors, 
especially to relatively low concentrations of antibacterial agents (Kawada-Matsuo 
2011;Gardete et al. 2006; Kuroda et al. 2003). Kuroda and co-workers (2003) discovered 
the vraSR operon by profiling genome-wide levels of transcription in a vraSR-null S. 
aureus strain, KVR. Sengupta and co-workers (2012) further identified genes under the 
direct regulation of VraR by its binding to their promoter regions. Belcheva and 
co-workers (2009) identified the regulatory mechanism of the binding of VraR to the 
vraSR promoter. They observed that the vraSR promoter harbored three distinct VraR 
binding sites with variable sequence features and affinities for VraR or phosphorylated 
VraR. The evidence suggests that the direct binding of VraR to promoters may be a 
general mechanism for regulating the transcription of related genes.  
I investigated the VraR binding activity on the promoter of fmtA. In vitro data 
indicated two VraR binding sites on the fmtA promoter: A1 and A2. The A2 site showed a 
higher affinity than the A1 site with VraR and phosphorylated VraR in both EMSAs and 
DNase I footprinting assays. The mutation of one or two essential nucleotides in the A2 
site effectively disrupted its interaction with VraR/phosphorylated VraR, while mutations 
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in the A1 site had no obvious effect. Mutations in the A1 site consistently had no effect on 
fmtA promoter strength in vivo in S. aureus RN4220 lux fusion strains, while mutation of 
the A2 site caused the loss of promoter strength under oxacillin treatment, suggesting that 
the A2 site may be the major VraR binding site in the fmtA promoter.  
Deleting the entire A1 site from the fmtA promoter had no effect on its promoter 
strength, and deleting the A1 site from the fmtA complementary strain did not change the 
transcriptional level of fmtA, as determined by qRT-PCR. These results suggest that the 
A1 site is not required for the regulation of fmtA transcription under oxacillin stress. 
The A2 site (-241ACTttAGTaTGAtgTCt-225) is similar to the R1 VraR binding site in 
the vraSR promoter and includes two putative VraR binding motifs, which are also 
conserved with the previously identified VraR binding motifs R1a (ACTaaAGT) and R1b 
(TGAacaTCA) in the vraSR promoter (Belcheva et al. 2009). These two motifs are 
separated by a single A in both promoters. Our research group has observed that mutating 
either of these two motifs in the A2 site could eliminate the upregulation of fmtA 
transcription under oxacillin stress (unpublished). I found that the insertion of an 
additional A between these two motifs had the same effect. These findings suggest that 
unphosphorylated VraR might not be able to bind to these two motifs unless they are 
dimerized.  
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Two transcription start sites, -157G and -195G, unlike in the vraSR operon, were 
identified in the fmtA promoter by primer extension and RLM-RACE. Previous extension 
assays also provided further evidence of VraR binding activity and of its binding 
mechanism on the fmtA promoter. Under non-stress conditions, -157G appears to be the 
major transcription start site, and the transcription is independent of oxacillin treatment. 
Transcription starting from -195G maintained a basal level in the absence of stress and 
corresponded to the upregulation of fmtA under oxacillin treatment. The vraR-mutated 
strain of RN4220 continued to express fmtA transcripts starting from -157G regardless of 
the presence of oxacillin, but the fmtA transcripts starting from -195G were not 
upregulated by oxacillin treatment, suggesting that oxacillin-induced VraR or 
phosphorylated VraR was responsible for the transcription initiated at -195G. 
murZ, sgtB and pbp2 encode essential enzymes involved in various steps of the 
biosynthesis of peptidoglycan. They also belong to the VraSR regulon family, and VraR 
modulates their transcription by directly binding to their promoters (Kuroda etal. 2003; 
Sengupta et al. 2012). The VraR/VraR~P-protected sequences in the DNase I footprinting 
assays have been identified in these promoters. A putative VraR binding region conserved 
with the VraR binding site A2 in the fmtA promoter and with the R1 binding site in the 
vraSR promoter has been observed in the murZ promoter. No similarly conserved regions, 
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however, have been found in the other two promoters, perhaps suggesting that VraR 
recognizes other types of specific sequences. 
This study identified the specific regulatory mechanism of fmtA transcription by 
VraR under oxacillin treatment. The VraR binding site A2 in the fmtA promoter is highly 
conserved with the R1 VraR binding site in the vraSR promoter, suggesting that this 
conservation could be a general feature in the VraSR regulon family. The lower amount of 
conservation in the sgtB and pbp2 promoters, however, also indicates that VraR may have 
other types of binding sites or different regulatory mechanisms for different VraSR 
regulon genes. The important role that the VraSR two-component system plays in 
resistance to environmental stress highlights the need to understand all VraR-mediated 
regulatory mechanisms. 
VraR, together with other factors, may coordinate the regulation of fmtA under the 
influence of cell-wall stressors (Sengupta et al. 2012; Zhao et al. 2012), so the 
identification of these other factors and their interactions would be a goal worth further 
research. The murZ promoter may be similar to the fmtA and vraSR promoters, and 
experiments similar to those in the present study could be designed to confirm this 
hypothesis. The specific VraR binding sites in the sgtB promoter should be determined, 
perhaps by EMSAs and DNase I footprinting assays where the VraR-protected regions are 
fragmented into shorter sequences. pbp2, though, has multiple transcription start sites and 
88 
 
shares the same operon with its upstream gene recU (Pinho et al. 1998), which would 
complicate the determination of the transcription start sites of pbp2. New primers would 
be required for primer-extension assays in the absence/presence of oxacillin treatment. 
The lack of conserved VraR binding sites in the pbp2 promoter is another challenge, so 
EMSAs and DNase I footprinting assays with shorter fragments could help to identify 
new VraR binding motifs. 
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Appendix 
  
Figure 1 Investigation of VraR/VraR~P binding affinity on A1a A1a-M4, 
A1b, A1b-M6 and A1c by EMSA. Kd values could not be determined 
accurately due to the range of available protein concentrations prepared in 
EMSA procedure. 
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Figure 2a Sequence of PmurZ. Double-underlined region is protected 
by VraR~P only in DNase I footprinting assays. Single-underlined 
region is protected by both VraR and VraR~P. Two conserved VraR 
binding motifs are highlighted by purple boxes. “*”s indicate predicted 
transcription start sites of murZ according to primer extension assays. 
Figure 2b Sequence of PsgtB. Double-underlined region is protected 
by VraR~P only in DNase I footprinting assays. Single-underlined 
region is protected by both VraR and VraR~P. Two conserved VraR 
binding motifs are highlighted by purple boxes. “*” indicates the 
predicted transcription start site of sgtB according to primer extension 
assays. 
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Figure 2c Sequence of Ppbp2. Double-underlined region is protected by 
VraR~P only in DNase I footprinting assays. “*”s indicate predicted 
transcription start sites of pbp2 according to primer extension assays. 
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Figure 3. Representive EMSA gels showing the EMSA analysis of the 
DNA-binding affinities of VraR/VraR~P to seq1-3, A1, A2 and their 
variants (corresponding to Figure 2.8). a) VraR and seq1-3; b) VraR and 
A2; c) VraR and A2-M1; d) VraR~P and Seq1-3; e) VraR~P and A2; f) 
VraR~P and A2-M1; g) VraR~P and A1; h) VraR~P and A1-M4; i) 
VraR~P and A1-M6.  
